Citation: Baldea, I.; Moldovan, R.;
Nagy, A.-L.; Bolfa, P .; Decea, R.;
Miclaus, M.O.; Lung, I.; Gherman,
A.M.R.; Sevastre-Berghian, A.; Martin,
F.A.; et al. Ketoconazole-Fumaric Acid
Pharmaceutical Cocrystal:
From Formulation Design for
Bioavailability Improvement to
Biocompatibility Testing and
Antifungal Efficacy Evaluation. Int. J.
Mol. Sci. 2024, 25, 13346. https://
doi.org/10.3390/ijms252413346
Academic Editors: Eugenia-Lenuta
Fagadar-Cosma and Alina Bora
Received: 11 November 2024
Revised: 9 December 2024
Accepted: 9 December 2024
Published: 12 December 2024
Copyright: © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Article
Ketoconazole-Fumaric Acid Pharmaceutical Cocrystal: From
Formulation Design for Bioavailability Improvement to
Biocompatibility Testing and Antifungal Efficacy Evaluation
Ioana Baldea 1
 , Remus Moldovan 1, Andras-Laszlo Nagy 2
 , Pompei Bolfa 2
 , Roxana Decea 1,
Maria Olimpia Miclaus 3, Ildiko Lung 3, Ana Maria Raluca Gherman 3
 , Alexandra Sevastre-Berghian 1,
Flavia Adina Martin 3, *, Irina Kacso 3, * and Vlad Răzniceanu 1
1 Department of Physiology, “Iuliu Ha¸ tieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca,
Romania; baldeaioana@gmail.com (I.B.); remus_ri@yahoo.com (R.M.); roxanadecea@yahoo.com (R.D.);
berghian.alexandra@umfcluj.ro (A.S.-B.); razniceanu.vlad@elearn.umfcluj.ro (V .R.)
2 Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre P .O. Box 334,
Saint Kitts and Nevis; anagy@rossvet.edu.kn (A.-L.N.); pompeibolfa@gmail.com (P .B.)
3 National Institute for R&D of Isotopic and Molecular Technologies, 400293 Cluj-Napoca, Romania;
maria.miclaus@itim.cj.ro (M.O.M.); ildiko.lung@itim-cj.ro (I.L.); raluca.gherman@itim-cj.ro (A.M.R.G.)
* Correspondence: flavia.martin@itim-cj.ro (F.A.M.); irina.kacso@itim-cj.ro (I.K.);
Tel.: +40-264584037 (F.A.M. & I.K.)
Abstract: Development of cocrystals through crystal engineering is a viable strategy to formulate
poorly water-soluble active pharmaceutical ingredients as stable crystalline solid forms with en-
hanced bioavailability. This study presents a controlled cocrystallization process by cooling for the 1:1
cocrystal of Ketoconazole, an antifungal class II drug with the Fumaric acid coformer. This was suc-
cessfully set up following the meta-stable zone width determination in acetone–water 4:6 (V/V) and
pure ethanol. Considering the optimal crystallization data, laboratory scale-up processes were carried
out at 1 g batch size, efficiently delivering the cocrystal in high yields up to 90% pure and single phase
as revealed by powder X-ray diffraction. Biological assays in vitro showed improved viability and ox-
idative damage of the cocrystal over Ketoconazole on human dermal fibroblasts and hepatocarcinoma
cells; in vivo, on Wistar rats, the cocrystal increased oral Ketoconazole bioavailability with transient
minor biochemical transaminases increases and without histological liver alterations. Locally on
Balb C mice, it induced no epicutaneuous sensitization. A molecular docking study conducted on
sterol 14α-demethylase (CYP51) enzyme from the pathogenic yeast Candida albicans revealed that the
cocrystal interacts more efficiently with the enzyme compared to Ketoconazole, indicating that the
coformer enhances the binding affinity of the active ingredient.
Keywords: ketoconazole; fumaric acid; cocrystal; biocompatibility; scale up; liver toxicity; pharma-
cokinetic profile
1. Introduction
The pharmaceutical industry is constantly working on designing new medicinal prod-
ucts with adequate bioavailability regarding the Active Pharmaceutical Ingredient (API)
solubility and intestinal permeability to provide an effective and safe treatment [1]. How-
ever, at present, up to 40% of APIs formulated as oral delivery drugs exhibit poor aqueous
solubility and dissolution rates (class II according to the Biopharmaceutical Classification
System, BCS [2]). These are critical aspects that affect the pharmaceutical potential [3]. Vari-
ous options are available to modulate the physicochemical and pharmacokinetic attributes
of the API without altering its chemical identity, such as lipid-based formulations [4], or
solid-state forms by rational use of crystal engineering [ 5]. This approach may conduct
to co-amorphous solid dispersions and a variety of crystalline forms, defined as salts,
hydrate/solvates, polymorphs, and cocrystals [6]. To date, the salt formulation is the most
Int. J. Mol. Sci. 2024, 25, 13346. https://doi.org/10.3390/ijms252413346 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2024, 25, 13346 2 of 28
widely applied strategy focused on the solubility enhancement of ionizable molecules;
therefore, almost 50% of drug products are developed in their salt form [7]. Additionally,
pharmaceutical cocrystal formulations represent another efficient alternative, aiming to
modify and improve the performance of API molecules [ 6]. Cocrystals are crystalline
structures composed of two or more neutral components connected via non-covalent
interactions at a precise stoichiometric ratio [ 8]. To form the pharmaceutical cocrystals,
mandatory coformers are required, namely the API and the pharmaceutically acceptable
ingredients considered appropriate for use (Generally Recognized as Safe, GRAS) [9]. In-
dustrial research in this area has led to regulatory approval of at least ten cocrystal-based
drug products. Several more are in the developing stage [5,10].
Ketoconazole (cis-1-acetyl-4-[4-[[(2RS,4SR)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-
ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine, KTZ) is a lipophilic imidazole
derivative, part of BCS class II, which exhibits a high permeability but low aqueous
solubility. KTZ was the first orally available azole for the systemic treatment of mycoses [11].
The antifungal properties are based on its ability to antagonize fungal cytochrome P450
enzymes such as lanosterol 14-α-demethylase. This prevents synthesis of ergosterol, an
important cell membrane component of the fungi that regulate permeability and structural
integrity [12]. Oral KTZ may be beneficial in the treatment of keratitis-ichthyosis-deafness
(KID) syndrome [13], mood disorders [14], as well as increasing the bioavailability of drugs
subject to intense CYP3A4 metabolization [15]. Topical application is recommended for
the treatment of localized and superficial dermatophytic infections such as candidiasis,
Malassezia-related seborrheic dermatitis, and tinea versicolor [ 16]. Although KTZ has
proven to be a versatile drug useful for both topical and systemic administration, post-
marketing reports of harmful drug interactions, hepatotoxicity, and adrenal insufficiency
have led the Committee for Medicinal Products for Human Use (CHMP) and the European
Medicines Agency (EMA) to recommend the suspension of KTZ oral usage in 2013, followed
by the FDA taking action to restrict KTZ-based systemic treatments [17]. On the other hand,
the benefits of the drug outweigh the risks, so it has been used off-label as a second-line
systemic therapy for castration-resistant prostate cancer [18]. Moreover, in 2014, the EMA
approved KTZ HRA for oral use to treat endogenous Cushing’s syndrome (including
paraneoplastic forms [19]), based on its inhibitory effect on adrenal enzymes CYP17A1,
CYP11B1, and CYP11B22, whereby it functions as a cortisol synthesis inhibitor. KTZ
intervenes in several androgen biosynthesis pathways by reducing CYP17A1 activity,
which makes it a useful option for the alleviation of symptoms and increasing survival in
cases of advanced prostate cancer [18,20].
Such developments in the KTZ therapeutic uses are an incentive to find and evaluate
new formulations that may reduce toxicity, improve efficacy, and increase bioavailability.
In this context, we have previously reported the ability of KTZ to form crystalline forms
with dicarboxylic acids in 1:1 stoichiometry, through the crystal engineering approach [21].
This research showed the highest aqueous solubility for the cocrystal obtained with the
Fumaric acid coformer, namely a 100-fold solubility increase vs. pure KTZ.
Fumaric acid (trans-2-butenedioic acid, FUM) is an organic compound involved in
metabolic pathways within human cells [ 22], and is generally used as a non-toxic food
additive intended for human consumption in order to combat the proliferation and activity
of harmful microorganisms such as bacteria and yeasts [23–25]. FUM and its derivatives
have various uses in medicine, mainly in the oral treatment of psoriasis and multiple
sclerosis, due to their effective immunomodulatory [26] and antioxidant effects [27]. Other
studies have shown that fumarate esters exhibit some anti-inflammatory effects in sarcoido-
sis, granuloma annulare, necrobiosis lipoidica, and antineoplastic activity in malignant
melanoma [28].
Administration of intraperitoneal injections with FUM in ICR mice with systemic
Candida albicans infections have prolonged survival and prevented one-fifth of deaths [29].
Different oral API formulations were shown to benefit from incorporating FUM. The
anti-inflammatory drug dexamethasone presented a greater synergistic effect with FUM,
Int. J. Mol. Sci. 2024, 25, 13346 3 of 28
which increased efficiency in the treatment of autoimmune and inflammatory diseases [30],
naftopidil solubility was improved in solid dispersion form [ 31], and the cocrystal with
pirfenidone exhibited a sustained-release behavior [32]. Furthermore, transdermal penetra-
tion of topical gels containing loxoprofen sodium was increased when FUM was used as
an enhancer [33].
In view of the potential health benefits that this cocrystal might have, the purpose of
the current study was to further (i) determine the limit of supersaturation up to which the
solution of the KTZ and FUM mixture is stable or metastable with respect to nucleation,
namely the metastable zone width (MSZW), to allow the setting of optimal parameters for
(ii) laboratory scale-up cocrystallization process; (iii) test the biocompatibilityin vitro on cell
cultures of human skin and liver cells, in view of potential local and systemic applications
of the KTZ-FUM and (iv) study the liver toxicity and bioavailability of the substance upon
oral administration in vivo on rat animal models, respectively, and epicutaneous skin
sensitization on mice models; as well as to (v) evaluate the binding affinity and binding
energy with biological molecules by a molecular docking study.
Our results evidenced that cocrystallization represents a successful approach for bio-
compatibility, oral bioavailability, local anti-inflammatory effects, and anti-fungal efficiency
enhancement of the poorly aqueous soluble drug KTZ, which supports further use of the
KTZ-FUM cocrystal in clinical studies.
2. Results
2.1. Controlled Cocrystallization Process by Cooling
The nucleation during the cooling step required for MSZW determination was ob-
tained in only two cases, namely the acetone–water 4:6 (V/V) mixture and pure ethanol,
with a cooling rate of 2 ◦C min−1 and 3 ◦C min−1, respectively (see the experimental
protocol, Section 4.2). The experimental conditions of the finalized tests are listed in Table 1,
and the unsuccessful experiments are illustrated accordingly in Table S1 (Supplementary
Materials).
Table 1. Cocrystallization experiments for MSZW determination.
Sample [KTZ] (mg mL −1) Solvent Yield (%)
C1.1 60
acetone–water 4:6
(V/V)
74
C1.2 80 71
C1.3 100 85
C1.4 120 78
C2.1 40
ethanol
74
C2.2 50 77
C2.3 60 72
C2.4 70 75
The resulting solid samples were subjected to PXRD; for all KTZ tested concentrations,
the cocrystal formation as a pure solid form is indicated in Figure 1. The cocrystalliza-
tion yields were above 70%, and the highest yield value of 85% was recorded for a KTZ
concentration of 100 mg mL−1 using the acetone–water 4:6 (V/V) mixture as a solvent.
Int. J. Mol. Sci. 2024, 25, 13346 4 of 28
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  4 of 28 
 
 
(Figure 2). The cocrystallization experiment by cooling was designed considering an ini‐
tial KTZ concentration of 100 mg mL−1, for which a wide operating range was observed in 
MSZW. Thus, complete dissolution of the product did not require a temperature higher 
than 60 °C. Cooling to room temperature induced nucleation and was enough to obtain a 
good cocrystallization yield of the cocrystal. 
(a)  (b) 
Figure 1. PXRD patterns of KTZ‐FUM cocrystal obtained by heating–cooling cycles in (a) acetone–
water 4:6 (V/V) and (b) ethanol. 
 
(a)  (b) 
Figure 2. MSZW of KTZ‐FUM cocrystal in (a) acetone–water 4:6 (V/V) and in (b) ethanol, the clear 
points (black) and the cloudy points (red). 
2.2. Scale‐Up Experiments of the Ketoconazol‐Fumaric Acid Cocrystal 
The cocrystallization parameters derived within the MSZW experiments were used 
as indicators for a viable and eﬀective laboratory up‐scaling of the cocrystal production 
to 1 g batch sizes. The ﬁrst series of scaling tests, namely SU‐E1 and SU‐E2, were per‐
formed applying the method of cocrystallization by cooling in solution using the syn‐
thesizer process station Eyela. The reaction conditions are detailed in Table 2. 
Table 2. Scale‐up conditions of KTZ‐FUM cocrystal by cooling cocrystallization in solution. 
Sample 
Cooling Cocrystallization in Solution 
Solvent/V (mL)  Tdis (°C) 1  Tpp (°C) 2  PXRD  Yield 
(%) 
SU‐E1  acetone–water 4:6 (V/V)/13  60  35  cocrystal  87 
SU‐E2  ethanol/18  62  31  cocrystal  89 
1 dissolution temperature, 2 precipitation temperature. 
As the PXRD investigation revealed, the KTZ‐FUM cocrystal was the only phase 
obtained in all resulting solid samples (Figure 3) with high scale‐up cocrystallization 
yields, up to around 90%. 
Figure 1. PXRD patterns of KTZ-FUM cocrystal obtained by heating–cooling cycles in (a) acetone–
water 4:6 (V/V) and (b) ethanol.
The parameters for a controlled cocrystallization process of KTZ-FUM were established
starting from the MSZW determined in acetone–water 4:6 (V/V) and in ethanol (Figure 2).
The cocrystallization experiment by cooling was designed considering an initial KTZ
concentration of 100 mg mL−1, for which a wide operating range was observed in MSZW.
Thus, complete dissolution of the product did not require a temperature higher than
60 ◦C. Cooling to room temperature induced nucleation and was enough to obtain a good
cocrystallization yield of the cocrystal.
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  4 of 28 
 
 
(Figure 2). The cocrystallization experiment by cooling was designed considering an ini‐
tial KTZ concentration of 100 mg mL−1, for which a wide operating range was observed in 
MSZW. Thus, complete dissolution of the product did not require a temperature higher 
than 60 °C. Cooling to room temperature induced nucleation and was enough to obtain a 
good cocrystallization yield of the cocrystal. 
(a)  (b) 
Figure 1. PXRD patterns of KTZ‐FUM cocrystal obtained by heating–cooling cycles in (a) acetone–
water 4:6 (V/V) and (b) ethanol. 
 
(a)  (b) 
Figure 2. MSZW of KTZ‐FUM cocrystal in (a) acetone–water 4:6 (V/V) and in (b) ethanol, the clear 
points (black) and the cloudy points (red). 
2.2. Scale‐Up Experiments of the Ketoconazol‐Fumaric Acid Cocrystal 
The cocrystallization parameters derived within the MSZW experiments were used 
as indicators for a viable and eﬀective laboratory up‐scaling of the cocrystal production 
to 1 g batch sizes. The ﬁrst series of scaling tests, namely SU‐E1 and SU‐E2, were per‐
formed applying the method of cocrystallization by cooling in solution using the syn‐
thesizer process station Eyela. The reaction conditions are detailed in Table 2. 
Table 2. Scale‐up conditions of KTZ‐FUM cocrystal by cooling cocrystallization in solution. 
Sample 
Cooling Cocrystallization in Solution 
Solvent/V (mL)  Tdis (°C) 1  Tpp (°C) 2  PXRD  Yield 
(%) 
SU‐E1  acetone–water 4:6 (V/V)/13  60  35  cocrystal  87 
SU‐E2  ethanol/18  62  31  cocrystal  89 
1 dissolution temperature, 2 precipitation temperature. 
As the PXRD investigation revealed, the KTZ‐FUM cocrystal was the only phase 
obtained in all resulting solid samples (Figure 3) with high scale‐up cocrystallization 
yields, up to around 90%. 
Figure 2. MSZW of KTZ-FUM cocrystal in (a) acetone–water 4:6 (V/V) and in (b) ethanol, the clear
points (black) and the cloudy points (red).
2.2. Scale-Up Experiments of the Ketoconazol-Fumaric Acid Cocrystal
The cocrystallization parameters derived within the MSZW experiments were used as
indicators for a viable and effective laboratory up-scaling of the cocrystal production to
1 g batch sizes. The first series of scaling tests, namely SU-E1 and SU-E2, were performed
applying the method of cocrystallization by cooling in solution using the synthesizer
process station Eyela. The reaction conditions are detailed in Table 2.
Table 2. Scale-up conditions of KTZ-FUM cocrystal by cooling cocrystallization in solution.
Sample
Cooling Cocrystallization in Solution
Solvent/V (mL) Tdis (◦C) 1 Tpp (◦C) 2 PXRD Yield (%)
SU-E1 acetone–water
4:6 (V/V)/13 60 35 cocrystal 87
SU-E2 ethanol/18 62 31 cocrystal 89
1 dissolution temperature, 2 precipitation temperature.
Int. J. Mol. Sci. 2024, 25, 13346 5 of 28
As the PXRD investigation revealed, the KTZ-FUM cocrystal was the only phase
obtained in all resulting solid samples (Figure 3) with high scale-up cocrystallization yields,
up to around 90%.
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  5 of 28 
 
 
 
Figure 3. PXRD patterns of the scaled‐up experiments of KTZ‐FUM cocrystal. 
The second cocrystallization approach for up‐scaling the KTZ‐FUM solid form was 
performed by the mechanochemistry strategy using a ball milling by wet grinding route. 
Initially, SDG cocrystallization experiments were performed using a reduced quantity of 
substances and solvents, i.e., 100 mg KTZ and two drops. PXRD analysis conﬁrmed the 
cocrystal form for each experimental condition, detailed in Table S2 and Figure S1 (see 
Supplementary Materials). Consequently, the up‐scale SDG synthesis based on 1 g KTZ 
was set up. The reaction conditions, e.g., solvent type/volume, reaction time (Table 3), 
were enough to yield the cocrystal as a pure form without traces of pure components, 
according to PXRD (Figure 3).  
Table 3. Scale‐up conditions for KTZ‐FUM cocrystal by mechanochemistry synthesis (SDG). 
Sample  Solvent Drop Grinding  
Solvent  V (μL)  PXRD 
SU‐SDG1  acetone–water 4:6 (V/V)  250  cocrystal 
SU‐SDG2  ethanol  250  cocrystal 
2.3. Biological Assays 
2.3.1. Cell Viability 
As seen in Figure 4, the cell viability of the BJ and HepG2 was decreased by both 
KTZ and KTZ‐FUM in a dose‐dependent manner, while Fumaric acid showed a minimal 
eﬀect. IC50 calculation showed that KTZ‐FUM was tolerated better by the cells (Table 4), 
when compared to the parent drug. In both cultures, Fumaric acid showed a low IC50, 
indicating the inhibition of cell proliferation, despite a small eﬀect on the cell viability as 
seen in Figure 4. 
 
(a)  (b) 
Figure 4. Cell viability of (a) dermal ﬁbroblasts and (b) hepatocarcinoma cells. Cells were exposed 
to diﬀerent concentrations of KTZ, KTZ‐FUM cocrystal, and FUM. Data are expressed as % of un‐
treated controls as mean± STDEV (n = 3) . A dotted line was drawn at 70%, representing the toxicity 
limit. 
Figure 3. PXRD patterns of the scaled-up experiments of KTZ-FUM cocrystal.
The second cocrystallization approach for up-scaling the KTZ-FUM solid form was
performed by the mechanochemistry strategy using a ball milling by wet grinding route.
Initially, SDG cocrystallization experiments were performed using a reduced quantity of
substances and solvents, i.e., 100 mg KTZ and two drops. PXRD analysis confirmed the
cocrystal form for each experimental condition, detailed in Table S2 and Figure S1 (see
Supplementary Materials). Consequently, the up-scale SDG synthesis based on 1 g KTZ
was set up. The reaction conditions, e.g., solvent type/volume, reaction time (Table 3), were
enough to yield the cocrystal as a pure form without traces of pure components, according
to PXRD (Figure 3).
Table 3. Scale-up conditions for KTZ-FUM cocrystal by mechanochemistry synthesis (SDG).
Sample
Solvent Drop Grinding
Solvent V ( µL) PXRD
SU-SDG1 acetone–water 4:6 ( V/V) 250 cocrystal
SU-SDG2 ethanol 250 cocrystal
2.3. Biological Assays
2.3.1. Cell Viability
As seen in Figure 4, the cell viability of the BJ and HepG2 was decreased by both
KTZ and KTZ-FUM in a dose-dependent manner, while Fumaric acid showed a minimal
effect. IC50 calculation showed that KTZ-FUM was tolerated better by the cells (Table 4),
when compared to the parent drug. In both cultures, Fumaric acid showed a low IC 50,
indicating the inhibition of cell proliferation, despite a small effect on the cell viability as
seen in Figure 4.
Table 4. IC50 calculated for cultures of BJ dermal fibroblasts and HepG2 hepatocarcinoma cells
subjected to various concentrations of KTZ, KTZ-FUM cocrystal, and FUM.
Cell Type KTZ ( µM) KTZ-FUM ( µM) Fumaric Acid ( µM)
BJ 7.45 42.39 7.26
HepG2 7.48 20.23 3.19
Int. J. Mol. Sci. 2024, 25, 13346 6 of 28
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  5 of 28 
 
 
 
Figure 3. PXRD patterns of the scaled‐up experiments of KTZ‐FUM cocrystal. 
The second cocrystallization approach for up‐scaling the KTZ‐FUM solid form was 
performed by the mechanochemistry strategy using a ball milling by wet grinding route. 
Initially, SDG cocrystallization experiments were performed using a reduced quantity of 
substances and solvents, i.e., 100 mg KTZ and two drops. PXRD analysis conﬁrmed the 
cocrystal form for each experimental condition, detailed in Table S2 and Figure S1 (see 
Supplementary Materials). Consequently, the up‐scale SDG synthesis based on 1 g KTZ 
was set up. The reaction conditions, e.g., solvent type/volume, reaction time (Table 3), 
were enough to yield the cocrystal as a pure form without traces of pure components, 
according to PXRD (Figure 3).  
Table 3. Scale‐up conditions for KTZ‐FUM cocrystal by mechanochemistry synthesis (SDG). 
Sample  Solvent Drop Grinding  
Solvent  V (μL)  PXRD 
SU‐SDG1  acetone–water 4:6 (V/V)  250  cocrystal 
SU‐SDG2  ethanol  250  cocrystal 
2.3. Biological Assays 
2.3.1. Cell Viability 
As seen in Figure 4, the cell viability of the BJ and HepG2 was decreased by both 
KTZ and KTZ‐FUM in a dose‐dependent manner, while Fumaric acid showed a minimal 
eﬀect. IC50 calculation showed that KTZ‐FUM was tolerated better by the cells (Table 4), 
when compared to the parent drug. In both cultures, Fumaric acid showed a low IC50, 
indicating the inhibition of cell proliferation, despite a small eﬀect on the cell viability as 
seen in Figure 4. 
 
(a)  (b) 
Figure 4. Cell viability of (a) dermal ﬁbroblasts and (b) hepatocarcinoma cells. Cells were exposed 
to diﬀerent concentrations of KTZ, KTZ‐FUM cocrystal, and FUM. Data are expressed as % of un‐
treated controls as mean± STDEV (n = 3) . A dotted line was drawn at 70%, representing the toxicity 
limit. 
Figure 4. Cell viability of (a) dermal fibroblasts and (b) hepatocarcinoma cells. Cells were exposed to
different concentrations of KTZ, KTZ-FUM cocrystal, and FUM. Data are expressed as % of untreated
controls as mean± STDEV (n = 3). A dotted line was drawn at 70%, representing the toxicity limit.
Oxidative damage induced by cell exposure to the KTZ, KTZ-FUM, and Fumaric
acid was evaluated by the measurement of malondialdehyde (MDA), a marker for lipid
peroxidation (Figure 5). MDA was decreased by both KTZ and KTZ-FUM. The latter
had a more pronounced effect, which was significant in fibroblasts compared to controls.
Fumaric acid had a smaller effect in fibroblasts and slightly increased MDA in HepG2, but
not significant.
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  6 of 28 
 
 
Table 4. IC50 calculated for cultures of BJ dermal ﬁbroblasts and HepG2 hepatocarcinoma cells 
subjected to various concentrations of KTZ, KTZ‐FUM cocrystal, and FUM. 
Cell Type  KTZ (μM)  KTZ‐FUM (μM)  Fumaric Acid (μM) 
BJ  7.45  42.39  7.26 
HepG2  7.48  20.23  3.19 
Oxidative damage induced by cell exposure to the KTZ, KTZ‐FUM, and Fumaric acid 
was evaluated by the measurement of malondialdehyde (MDA), a marker for lipid perox‐
idation (Figure 5). MDA was decreased by both KTZ and KTZ‐FUM. The latter had a more 
pronounced effect, which was significant in fibroblasts compared to controls. Fumaric acid 
had a smaller effect in fibroblasts and slightly increased MDA in HepG2, but not signifi‐
cant. 
(a)  (b) 
Figure 5. Malondialdehyde—MDA  of (a) dermal ﬁbroblasts and (b) hepatocarcinoma cells. Cells 
were exposed to KTZ, KTZ‐FUM, and FUM in a concentration of 6 µM of each substance. Data are 
expressed as % of untreated controls as mean± STDEV (n = 3), * = p ≤ 0.05. 
2.3.2. Pharmaco‐Dynamic Proﬁle 
In our experiments, the relative calculated bioavailability of the KTZ‐FUM cocrystal 
over KTZ, after a unique oral dose, was F = 12.79. This indicates a higher bioavailability of the 
cocrystal compared to the parent drug. As seen in Figure 6 and Table 5, the peak for 
KTZ‐FUM was reached at 1 h. The maximum concentration KTZ‐FUM reached was 8.97 × 
more than the one for KTZ, which indicates a higher absorption rate from the gut. KTZ‐FUM 
was still detected in plasma at 24 h compared to KTZ, which was not detected after 6 h, in‐
dicating that the cocrystal formulation allows for a prolonged release. These data show an 
improvement in the pharmaco‐kinetic profile of the KTZ‐FUM cocrystal compared to pure 
KTZ. 
 
Figure 5. Malondialdehyde—MDA of (a) dermal fibroblasts and (b) hepatocarcinoma cells. Cells
were exposed to KTZ, KTZ-FUM, and FUM in a concentration of 6 µM of each substance. Data are
expressed as % of untreated controls as mean± STDEV (n = 3), * = p ≤ 0.05.
2.3.2. Pharmaco-Dynamic Profile
In our experiments, the relative calculated bioavailability of the KTZ-FUM cocrystal
over KTZ, after a unique oral dose, was F = 12.79. This indicates a higher bioavailability
of the cocrystal compared to the parent drug. As seen in Figure 6 and Table 5, the peak
for KTZ-FUM was reached at 1 h. The maximum concentration KTZ-FUM reached was
8.97 × more than the one for KTZ, which indicates a higher absorption rate from the gut.
KTZ-FUM was still detected in plasma at 24 h compared to KTZ, which was not detected
after 6 h, indicating that the cocrystal formulation allows for a prolonged release. These
data show an improvement in the pharmaco-kinetic profile of the KTZ-FUM cocrystal
compared to pure KTZ.
Int. J. Mol. Sci. 2024, 25, 13346 7 of 28
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  6 of 28 
 
 
Table 4. IC50 calculated for cultures of BJ dermal ﬁbroblasts and HepG2 hepatocarcinoma cells 
subjected to various concentrations of KTZ, KTZ‐FUM cocrystal, and FUM. 
Cell Type  KTZ (μM)  KTZ‐FUM (μM)  Fumaric Acid (μM) 
BJ  7.45  42.39  7.26 
HepG2  7.48  20.23  3.19 
Oxidative damage induced by cell exposure to the KTZ, KTZ‐FUM, and Fumaric acid 
was evaluated by the measurement of malondialdehyde (MDA), a marker for lipid perox‐
idation (Figure 5). MDA was decreased by both KTZ and KTZ‐FUM. The latter had a more 
pronounced effect, which was significant in fibroblasts compared to controls. Fumaric acid 
had a smaller effect in fibroblasts and slightly increased MDA in HepG2, but not signifi‐
cant. 
(a)  (b) 
Figure 5. Malondialdehyde—MDA  of (a) dermal ﬁbroblasts and (b) hepatocarcinoma cells. Cells 
were exposed to KTZ, KTZ‐FUM, and FUM in a concentration of 6 µM of each substance. Data are 
expressed as % of untreated controls as mean± STDEV (n = 3), * = p ≤ 0.05. 
2.3.2. Pharmaco‐Dynamic Proﬁle 
In our experiments, the relative calculated bioavailability of the KTZ‐FUM cocrystal 
over KTZ, after a unique oral dose, was F = 12.79. This indicates a higher bioavailability of the 
cocrystal compared to the parent drug. As seen in Figure 6 and Table 5, the peak for 
KTZ‐FUM was reached at 1 h. The maximum concentration KTZ‐FUM reached was 8.97 × 
more than the one for KTZ, which indicates a higher absorption rate from the gut. KTZ‐FUM 
was still detected in plasma at 24 h compared to KTZ, which was not detected after 6 h, in‐
dicating that the cocrystal formulation allows for a prolonged release. These data show an 
improvement in the pharmaco‐kinetic profile of the KTZ‐FUM cocrystal compared to pure 
KTZ. 
 
Figure 6. Pharmaco-dynamic profile of KTZ and KTZ-FUM after one oral dose (20 mg kg−1 bw) in
Wistar rats. Data represent the mean ± STDEV (n = 3).
Table 5. Pharmaco-kinetic data of KTZ-FUM and KTZ in Wistar rats after one dose (20 mg kg−1 bw),
oral administration.
Unit KTZ-FUM KTZ
AUC0–24h a µg h mL−1 2930.4 ± 0.1 228.96 ± 0.11
Cmax b µg mL−1 52.213 ± 2.04 5.82 ± 0.7
a area under serum concentration of each substance/time curve for 24 h, calculated using GraphPad software
Prism version 4.00 for Windows; b maximum serum concentration of the drug.
2.3.3. Hepatotoxicity
Liver injuries induced by a single oral dose of KTZ-FUM (20 mg kg −1 bw) were
assessed in dynamics by two methods, the biochemical measurement of liver transaminases
(AST-aspartate aminotransferase, ALT-alanine transaminase and ratio of AST/ALT) from
serum (Figure 7), and the histopathology examination of liver samples (Figure 8). AST, the
most important transaminase, decreased in the first 15 min. after the oral administration of
KTZ-FUM, then it gradually increased to reach a first peak at 4 h, then a second peak at
8 h; afterwards, it decreased till 7 days, but it remained at a slightly higher level compared
to controls. ALT dynamics showed a different trend, with an initial low peak at 15 min,
then lower values compared to controls, and then a slow increase until 7 days. The ratio of
AST/ALT showed higher values compared to the control until 24 h, with the maximum
reached at 8 h. At 7 days, the ratio of AST/ALT was slightly below the control (Figure 7).
For all measurements, the Kruskall–Wallis test indicated significant dynamics compared to
controls (p ≤ 0.0012), but no significance was found between the individual time points
(Dunn’s multiple comparison test—p > 0.05).
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  7 of 28 
 
 
Figure 6. Pharmaco‐dynamic proﬁle of KTZ and KTZ‐FUM after one oral dose (20 mg kg−1 bw) in 
Wistar rats. Data represent the mean ± STDEV (n = 3). 
Table 5. Pharmaco‐kinetic data of KTZ‐FUM and KTZ in Wistar rats after one dose (20 mg kg−1 bw), 
oral administration. 
  Unit  KTZ‐FUM  KTZ 
AUC0–24h a  µg h mL−1  2930.4 ± 0.1  228.96 ± 0.11 
Cmax b  µg mL−1  52.213 ± 2.04  5.82 ± 0.7 
a area under serum concentration of each substance/time curve for 24 h, calculated using GraphPad 
software Prism version 4.00 for Windows; b maximum serum concentration of the drug. 
2.3.3. Hepatotoxicity 
Liver injuries induced by a single oral dose of KTZ‐FUM (20 mg kg−1 bw) were as‐
sessed in dynamics by two methods, the biochemical measurement of liver transaminases 
(AST‐aspartate aminotransferase, ALT‐alanine transaminase and ratio of AST/ALT) from 
serum (Figure 7), and the histopathology examination of liver samples (Figure 8). AST, 
the most important transaminase, decreased in the ﬁrst 15 min. after the oral administra‐
tion of KTZ‐FUM, then it gradually increased to reach a ﬁrst peak at 4 h, then a second 
peak at 8 h; afterwards, it decreased till 7 days, but it remained at a slightly higher level 
compared to controls. ALT dynamics showed a diﬀerent trend, with an initial low peak at 
15 min., then lower values compared to controls, and then a slow increase until 7 days. 
The ratio of AST/ALT showed higher values compared to the control until 24 h, with the 
maximum reached at 8 h. At 7 days, the ratio of AST/ALT was slightly below the control 
(Figure 7). For all measurements, the Kruskall–Wallis test indicated signiﬁcant dynamics 
compared to controls (p ≤ 0.0012), but no signiﬁcance was found between the individual 
time points (Dunn’s multiple comparison test— p > 0.05). 
 
(a)  (b)  (c) 
Figure 7. Comparative measurement of transaminases ratio (a) AST/ALT, (b) AST, and (c) ALT 
from the Wistar rats’ serum after one dose of KTZ‐FUM (20 mg kg−1 bw), oral administration. Data 
represent the mean ± STDEV (n = 3). 
2.3.4. Liver Sections 
Histologically, the liver was similar in both the control and treated groups and at all 
time points. Samples showed normal hepatic architecture, without evidence of toxic 
changes or inﬂammation (Figure 8). 
To evaluate the possible protection against the oxidative stress and inﬂammation 
induced by the cocrystal in the liver tissue due to the Fumaric acid, we measured the 
MDA and TNFα at diﬀerent time points (Figure 9) following the oral administration. In 
the liver, the data showed minimal oxidative lipid peroxidation, starting as soon as 30 
min., and reversible within 24 h. This ﬁnding was combined with minimal changes in the 
pro‐inﬂammatory cytokine TNFα, despite the persistence of KTZ‐FUM in the blood‐
stream at this time point. For all measurements, the Kruskall–Wallis test indicated no 
signiﬁcant dynamics compared to controls (p ≥ 0.05). 
Figure 7. Comparative measurement of transaminases ratio ( a) AST/ALT, (b) AST, and ( c) ALT
from the Wistar rats’ serum after one dose of KTZ-FUM (20 mg kg−1 bw), oral administration. Data
represent the mean ± STDEV (n = 3).
Int. J. Mol. Sci. 2024, 25, 13346 8 of 28
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  8 of 28 
 
 
 
Figure 8. Histopathological images of the liver from the animals exposed to KTZ‐FUM for diﬀerent 
time points, microphotographs centered on the centrilobular area: (a) control, (b) KTZ‐FUM ex‐
posure for 30 min, (c) 24 h, (d) 7 days, (e) KTZ exposure for 30 min, (f) 24 h, (g) 7 days. All sections 
show normal hepatic architecture. HE stain, Bar = 20 µm. 
(a)  (b) 
Figure 9. Measurement of (a) MDA and (b) TNFα from Wistar rat liver samples taken at diﬀerent 
time points after one dose of KTZ‐FUM (20 mg kg−1 bw), oral administration. Data represent the 
mean ± STDEV (n = 3). 
2.3.5. Hematology and Biochemistry Measurements 
Oral KTZ‐FUM administration in Wistar rats led to an increase in the red blood cells 
and platelet counts as soon as 30 min, then the red blood cell counts slowly returned to 
normal at 72 h. The platelets number remained signiﬁcantly higher compared to the 
control. Levels of cholesterol and glucose were not altered by the KTZ‐FUM administra‐
tion (Table 6). 
Table 6. Hematology and biochemistry assessment following oral KTZ‐FUM administration. 
  RBC  Hb  HTC  WBC  PLT  CST  Glucose 
  (×106)  (g dL−1)  (%)  (×103)  (×103)  (mg dL−1)  (mg dL−1) 
CTRL  7.62 ± 0.41  13.90 ± 0.41  41.30 ± 0.84  10.95 ± 0.40  580.01 ± 15.56  35.3 ± 0.53  80.69 ± 5.34 
0.5 h  8.27 ± 0.92 *  15.9 ± 0.867  49.63 ± 2.82  9.17 ± 2.72  687.66 ± 47.24 *  33.35 ± 3.69  82.77 ± 0.28 
24 h  8.22 ± 0.54  15.9 ± 0.1 *  48.03 ± 0.11  7.91 ± 2.89  747 ± 234.78  35.45 ± 2.26  82.9 ± 7.47 
72 h  7.4 ± 0.62  14.26 ± 1.41  44.73 ± 3.91  9.09 ± 4.68  753.33 ± 45.05 *  31.95 ± 2.07  81.56 ± 4.65 
RBC—red   blood  cells,  Hb—hemoglobin,   HTC—hematocrit,   WBC—white   blood  cells, 
PLT—platelets,  CST—total  cholesterol; data are presented as mean ± STDEV, n = 3 for each meas‐
urement; statistical analysis was performed using Student TTEST, * = p < 0.05. 
2.3.6. Epicutaneous Sensitization Test 
Figure 8. Histopathological images of the liver from the animals exposed to KTZ-FUM for different
time points, microphotographs centered on the centrilobular area: (a) control, (b) KTZ-FUM exposure
for 30 min, (c) 24 h, (d) 7 days, (e) KTZ exposure for 30 min, (f) 24 h, (g) 7 days. All sections show
normal hepatic architecture. HE stain, Bar = 20 µm.
2.3.4. Liver Sections
Histologically, the liver was similar in both the control and treated groups and at
all time points. Samples showed normal hepatic architecture, without evidence of toxic
changes or inflammation (Figure 8).
To evaluate the possible protection against the oxidative stress and inflammation
induced by the cocrystal in the liver tissue due to the Fumaric acid, we measured the MDA
and TNFα at different time points (Figure 9) following the oral administration. In the
liver, the data showed minimal oxidative lipid peroxidation, starting as soon as 30 min.,
and reversible within 24 h. This finding was combined with minimal changes in the pro-
inflammatory cytokine TNFα, despite the persistence of KTZ-FUM in the bloodstream at
this time point. For all measurements, the Kruskall–Wallis test indicated no significant
dynamics compared to controls (p ≥ 0.05).
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  8 of 28 
 
 
 
Figure 8. Histopathological images of the liver from the animals exposed to KTZ‐FUM for diﬀerent 
time points, microphotographs centered on the centrilobular area: (a) control, (b) KTZ‐FUM ex‐
posure for 30 min, (c) 24 h, (d) 7 days, (e) KTZ exposure for 30 min, (f) 24 h, (g) 7 days. All sections 
show normal hepatic architecture. HE stain, Bar = 20 µm. 
(a)  (b) 
Figure 9. Measurement of (a) MDA and (b) TNFα from Wistar rat liver samples taken at diﬀerent 
time points after one dose of KTZ‐FUM (20 mg kg−1 bw), oral administration. Data represent the 
mean ± STDEV (n = 3). 
2.3.5. Hematology and Biochemistry Measurements 
Oral KTZ‐FUM administration in Wistar rats led to an increase in the red blood cells 
and platelet counts as soon as 30 min, then the red blood cell counts slowly returned to 
normal at 72 h. The platelets number remained signiﬁcantly higher compared to the 
control. Levels of cholesterol and glucose were not altered by the KTZ‐FUM administra‐
tion (Table 6). 
Table 6. Hematology and biochemistry assessment following oral KTZ‐FUM administration. 
  RBC  Hb  HTC  WBC  PLT  CST  Glucose 
  (×106)  (g dL−1)  (%)  (×103)  (×103)  (mg dL−1)  (mg dL−1) 
CTRL  7.62 ± 0.41  13.90 ± 0.41  41.30 ± 0.84  10.95 ± 0.40  580.01 ± 15.56  35.3 ± 0.53  80.69 ± 5.34 
0.5 h  8.27 ± 0.92 *  15.9 ± 0.867  49.63 ± 2.82  9.17 ± 2.72  687.66 ± 47.24 *  33.35 ± 3.69  82.77 ± 0.28 
24 h  8.22 ± 0.54  15.9 ± 0.1 *  48.03 ± 0.11  7.91 ± 2.89  747 ± 234.78  35.45 ± 2.26  82.9 ± 7.47 
72 h  7.4 ± 0.62  14.26 ± 1.41  44.73 ± 3.91  9.09 ± 4.68  753.33 ± 45.05 *  31.95 ± 2.07  81.56 ± 4.65 
RBC—red   blood  cells,  Hb—hemoglobin,   HTC—hematocrit,   WBC—white   blood  cells, 
PLT—platelets,  CST—total  cholesterol; data are presented as mean ± STDEV, n = 3 for each meas‐
urement; statistical analysis was performed using Student TTEST, * = p < 0.05. 
2.3.6. Epicutaneous Sensitization Test 
Figure 9. Measurement of (a) MDA and (b) TNFα from Wistar rat liver samples taken at different
time points after one dose of KTZ-FUM (20 mg kg−1 bw), oral administration. Data represent the
mean ± STDEV (n = 3).
2.3.5. Hematology and Biochemistry Measurements
Oral KTZ-FUM administration in Wistar rats led to an increase in the red blood cells
and platelet counts as soon as 30 min, then the red blood cell counts slowly returned
to normal at 72 h. The platelets number remained significantly higher compared to the
Int. J. Mol. Sci. 2024, 25, 13346 9 of 28
control. Levels of cholesterol and glucose were not altered by the KTZ-FUM administration
(Table 6).
Table 6. Hematology and biochemistry assessment following oral KTZ-FUM administration.
RBC Hb HTC WBC PLT CST Glucose
(×106) (g dL−1) (%) (×103) ( ×103) (mg dL−1) (mg dL −1)
CTRL 7.62 ± 0.41 13.90 ± 0.41 41.30 ± 0.84 10.95 ± 0.40 580.01 ± 15.56 35.3 ± 0.53 80.69 ± 5.34
0.5 h 8.27 ± 0.92 * 15.9 ± 0.867 49.63 ± 2.82 9.17 ± 2.72 687.66 ± 47.24 * 33.35 ± 3.69 82.77 ± 0.28
24 h 8.22 ± 0.54 15.9 ± 0.1 * 48.03 ± 0.11 7.91 ± 2.89 747 ± 234.78 35.45 ± 2.26 82.9 ± 7.47
72 h 7.4 ± 0.62 14.26 ± 1.41 44.73 ± 3.91 9.09 ± 4.68 753.33 ± 45.05 * 31.95 ± 2.07 81.56 ± 4.65
RBC—red blood cells, Hb—hemoglobin, HTC—hematocrit, WBC—white blood cells, PLT—platelets, CST—total
cholesterol; data are presented as mean ± STDEV , n = 3 for each measurement; statistical analysis was performed
using Student TTEST, * = p < 0.05.
2.3.6. Epicutaneous Sensitization Test
We tested the epicutaneous sensitization potential of the cocrystal KTZ-FUM in com-
parison with the parent drug KTZ and Fumaric acid by using the mouse ear sensitization
test (MEST). The positive control was represented by dinitrochlorobenzene (DNCB) and the
negative control by the vehicle (70% ethylic alcohol). The positive control animals showed a
high increase in ear thickness, starting at 48 h after challenge. This increase was maintained
at rechallenge, with a maximum at R 24 h (Figure 10). In all the other groups, there was no
alteration in ear thickness during the test. Two-way ANOVA showed significant time and
treatment interaction between the groups (p < 0.0001).
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  9 of 28 
 
 
We tested the epicutaneous sensitization potential of the cocrystal KTZ‐FUM in 
comparison with the parent drug KTZ and Fumaric acid by using the mouse ear sensiti‐
zation  test  (MEST).  The  positive  control  was  represented  by  dinitrochlorobenzene 
(DNCB) and the negative control by the vehicle (70% ethylic alcohol). The positive control 
animals showed a high increase in ear thickness, starting at 48 h after challenge. This in‐
crease was maintained at rechallenge, with a maximum at R 24 h (Figure 10). In all the 
other groups, there was no alteration in ear thickness during the test. Two‐way ANOVA 
showed signiﬁcant time and treatment interaction between the groups (p < 0.0001). 
 
Figure 10. Mouse ear sensitization test. Comparative ear thickness in mice at diﬀerent time points 
during the test, C 24 h—24  h after challenge, C 48 h—48  h after challenge, R 24 h—24  h after re‐
challenge, R 48 h—48  h after challenge; experimental groups: 1. negative control—represented  by 
the vehicle, 2. KTZ, 3. KTZ‐FUM, 4. FUM, and 5. positive control—represented  by DNCB. Data are 
presented as mean ± STDEV (n = 5), *** = p ≤ 0.001. 
To  further  explore  the  inﬂammatory potential of the  locally applied  KTZ‐FUM 
compared to the parent drug, we measured the inﬂammatory cytokines IL6 and IL1α and 
β in the treated ear tissue (Figure 11). As expected, the DNCB group showed a signiﬁcant 
increase compared to the control of all cytokines. KTZ and FUM increased IL6, while 
IL1α and β were decreased, showing a low anti‐inﬂammatory eﬀect, although not sig‐
niﬁcant. KTZ‐FUM induced the decrease in IL6 and IL1α, showing anti‐inﬂammatory 
potential. The Kruskall–Wallis test showed signiﬁcance between groups for IL6 and IL1α 
(p ≤ 0.04) and not for IL1β (p = 0.09). 
    
(a)  (b)  (c) 
Figure 11. Inﬂammatory markers measured from the ear tissue collected at R48 h through ELISA 
(a) IL1α, (b) IL1β, and (c) IL6. Experimental groups: 1. negative control—represented  by the vehi‐
cle, 2. KTZ, 3. KTZ‐FUM, 4. FUM, and 5. positive control—represented  by DNCB. Data are pre‐
sented as mean± STDEV (n = 3), ** = p ≤ 0.01, *** = p ≤ 0.001. 
2.3.7. Histopathology of Ear Sections 
In the DNCB‐treated group, histological exam revealed contact dermatitis, with 
mo‐derate inﬂammation, epidermal spongiosis in the basal and spinous layers, slight 
dermal edema, and multifocal inﬂammatory inﬁltration with lymphocytes and plasma 
Figure 10. Mouse ear sensitization test. Comparative ear thickness in mice at different time points
during the test, C 24 h—24 h after challenge, C 48 h—48 h after challenge, R 24 h—24 h after
rechallenge, R 48 h—48 h after challenge; experimental groups: 1. negative control—represented by
the vehicle, 2. KTZ, 3. KTZ-FUM, 4. FUM, and 5. positive control—represented by DNCB. Data are
presented as mean ± STDEV (n = 5), *** = p ≤ 0.001.
To further explore the inflammatory potential of the locally applied KTZ-FUM com-
pared to the parent drug, we measured the inflammatory cytokines IL6 and IL1α and β
in the treated ear tissue (Figure 11). As expected, the DNCB group showed a significant
increase compared to the control of all cytokines. KTZ and FUM increased IL6, while IL1α
and β were decreased, showing a low anti-inflammatory effect, although not significant.
KTZ-FUM induced the decrease in IL6 and IL1 α, showing anti-inflammatory potential.
The Kruskall–Wallis test showed significance between groups for IL6 and IL1α (p ≤ 0.04)
and not for IL1β (p = 0.09).
Int. J. Mol. Sci. 2024, 25, 13346 10 of 28
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  9 of 28 
 
 
We tested the epicutaneous sensitization potential of the cocrystal KTZ‐FUM in 
comparison with the parent drug KTZ and Fumaric acid by using the mouse ear sensiti‐
zation  test  (MEST).  The  positive  control  was  represented  by  dinitrochlorobenzene 
(DNCB) and the negative control by the vehicle (70% ethylic alcohol). The positive control 
animals showed a high increase in ear thickness, starting at 48 h after challenge. This in‐
crease was maintained at rechallenge, with a maximum at R 24 h (Figure 10). In all the 
other groups, there was no alteration in ear thickness during the test. Two‐way ANOVA 
showed signiﬁcant time and treatment interaction between the groups (p < 0.0001). 
 
Figure 10. Mouse ear sensitization test. Comparative ear thickness in mice at diﬀerent time points 
during the test, C 24 h—24  h after challenge, C 48 h—48  h after challenge, R 24 h—24  h after re‐
challenge, R 48 h—48  h after challenge; experimental groups: 1. negative control—represented  by 
the vehicle, 2. KTZ, 3. KTZ‐FUM, 4. FUM, and 5. positive control—represented  by DNCB. Data are 
presented as mean ± STDEV (n = 5), *** = p ≤ 0.001. 
To  further  explore  the  inﬂammatory potential of the  locally applied  KTZ‐FUM 
compared to the parent drug, we measured the inﬂammatory cytokines IL6 and IL1α and 
β in the treated ear tissue (Figure 11). As expected, the DNCB group showed a signiﬁcant 
increase compared to the control of all cytokines. KTZ and FUM increased IL6, while 
IL1α and β were decreased, showing a low anti‐inﬂammatory eﬀect, although not sig‐
niﬁcant. KTZ‐FUM induced the decrease in IL6 and IL1α, showing anti‐inﬂammatory 
potential. The Kruskall–Wallis test showed signiﬁcance between groups for IL6 and IL1α 
(p ≤ 0.04) and not for IL1β (p = 0.09). 
    
(a)  (b)  (c) 
Figure 11. Inﬂammatory markers measured from the ear tissue collected at R48 h through ELISA 
(a) IL1α, (b) IL1β, and (c) IL6. Experimental groups: 1. negative control—represented  by the vehi‐
cle, 2. KTZ, 3. KTZ‐FUM, 4. FUM, and 5. positive control—represented  by DNCB. Data are pre‐
sented as mean± STDEV (n = 3), ** = p ≤ 0.01, *** = p ≤ 0.001. 
2.3.7. Histopathology of Ear Sections 
In the DNCB‐treated group, histological exam revealed contact dermatitis, with 
mo‐derate inﬂammation, epidermal spongiosis in the basal and spinous layers, slight 
dermal edema, and multifocal inﬂammatory inﬁltration with lymphocytes and plasma 
Figure 11. Inflammatory markers measured from the ear tissue collected at R48 h through ELISA
(a) IL1α, (b) IL1β, and (c) IL6. Experimental groups: 1. negative control—represented by the vehicle,
2. KTZ, 3. KTZ-FUM, 4. FUM, and 5. positive control—represented by DNCB. Data are presented as
mean ± STDEV (n = 3), ** = p ≤ 0.01, *** = p ≤ 0.001.
2.3.7. Histopathology of Ear Sections
In the DNCB-treated group, histological exam revealed contact dermatitis, with mo-
derate inflammation, epidermal spongiosis in the basal and spinous layers, slight dermal
edema, and multifocal inflammatory infiltration with lymphocytes and plasma cells. No
histological changes were seen in the control–vehicle-treated group, KTZ, FUM, and in the
KTZ-FUM-treated group (Figure 12).
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  10 of 28 
 
 
cells. No histological changes were seen in the control–vehicle‐treated group, KTZ, FUM, 
and in the KTZ‐FUM‐treated group (Figure 12). 
 
Figure 12. Histological analysis of ear pinna following the mouse ear sensitization test—( a) vehi‐
cle‐negative control‐ (b) KTZ‐ (c) FUM‐, and (d) KTZ‐FUM‐treated mice showed normal histological 
features, such as keratinized epithelium (arrowheads), and dermal structures (connective tissue, 
vessels,  and  adnexal  structures)  without  any  inflammatory  changes;  (e)  DNCB‐positive  control. 
DNCB‐treated mice exhibited contact dermatitis characterized by increased ear overall thickness, 
compared to vehicle and the other treated  groups. The epithelium was multifocally irregularly 
thickened, with epidermal spongiosis (stars) in the basal and spinous layer. The dermis had mild, 
multifocal inflammatory infiltration with lymphocytes and plasma cells (arrows) and edema. HE 
stain. Bar = 100 µm. 
2.4. Molecular Docking Study 
The binding energies of KTZ, FUM, cocrystal, and posaconazole (original ligand) to 
the sterol 14α‐demethylase enzyme from Candida albicans (PDB id: 5FSA) were predicted 
via molecular docking (Table 7). 
Table 7. Binding aﬃnities of KTZ, FUM, KTZ‐FUM cocrystal, and posaconazole to 14‐α deme‐
thylase from Candida albicans (PDB id: 5FSA). 
kcal mol−1  KTZ  FUM  Cocrystal  Original 
average Ebind   −11.36 − 4.50 − 12.54 − 12.08 
SD   0.31  0.00  0.23  0.14 
min − 11.70 − 4.50 − 12.80 − 12.30 
max − 10.10 − 4.50 − 11.60 − 11.80 
Binding aﬃnities expressed as average values for the best ligand of the 20 code runs together with 
the standard deviation (SD), as well as the min and max values obtained within the 20 code runs. 
Posaconazole, the original ligand, scored a binding energy of −12.08 ± 0.14 kcal 
mol−1. FUM enhanced KTZ’s binding energy by more than 1 kcal mol−1. Among all stud‐
ied  systems,  the  KTZ‐FUM  cocrystal–sterol  14α‐demethylase  complex  exhibited  the 
lowest binding energy (−12.54 ± 0.23 kcal mol−1). This value for the binding energy indi‐
cates that the cocrystal had the highest aﬃnity within the tested systems. 
The binding site of sterol 14α‐demethylase, positioned in the interior of the macro‐
molecule near the heme group, forms a pocket‐like structure (Figure 13) that promotes 
the geometrical speciﬁcity of ligands to the detriment of other types of interactions. This 
site is deﬁned by the following amino acids: LEU87, LEU88, LYS90, MET92, LEU121, 
THR122, ILE131, TYR 132, PHE228, PRO230, PHE233, LEU300, ILE304, GLY307, THR311, 
LEU376, HIS377, SER378, PHE380, SER507, TYR401, SER507, MET508. 
Figure 12. Histological analysis of ear pinna following the mouse ear sensitization test—(a) vehicle-
negative control- (b) KTZ- (c) FUM-, and (d) KTZ-FUM-treated mice showed normal histological
features, such as keratinized epithelium (arrowheads), and dermal structures (connective tissue,
vessels, and adnexal structures) without any inflammatory changes; ( e) DNCB-positive control.
DNCB-treated mice exhibited contact dermatitis characterized by increased ear overall thickness,
compared to vehicle and the other treated groups. The epithelium was multifocally irregularly
thickened, with epidermal spongiosis (stars) in the basal and spinous layer. The dermis had mild,
multifocal inflammatory infiltration with lymphocytes and plasma cells (arrows) and edema. HE
stain. Bar = 100 µm.
2.4. Molecular Docking Study
The binding energies of KTZ, FUM, cocrystal, and posaconazole (original ligand) to
the sterol 14α-demethylase enzyme from Candida albicans (PDB id: 5FSA) were predicted
via molecular docking (Table 7).
Int. J. Mol. Sci. 2024, 25, 13346 11 of 28
Table 7. Binding affinities of KTZ, FUM, KTZ-FUM cocrystal, and posaconazole to 14-α demethylase
from Candida albicans (PDB id: 5FSA).
kcal mol−1 KTZ FUM Cocrystal Original
average Ebind −11.36 −4.50 −12.54 −12.08
SD 0.31 0.00 0.23 0.14
min −11.70 −4.50 −12.80 −12.30
max −10.10 −4.50 −11.60 −11.80
Binding affinities expressed as average values for the best ligand of the 20 code runs together with the standard
deviation (SD), as well as the min and max values obtained within the 20 code runs.
Posaconazole, the original ligand, scored a binding energy of −12.08 ± 0.14 kcal
mol−1. FUM enhanced KTZ’s binding energy by more than 1 kcal mol −1. Among all
studied systems, the KTZ-FUM cocrystal–sterol 14α-demethylase complex exhibited the
lowest binding energy ( −12.54 ± 0.23 kcal mol −1). This value for the binding energy
indicates that the cocrystal had the highest affinity within the tested systems.
The binding site of sterol 14α-demethylase, positioned in the interior of the macro-
molecule near the heme group, forms a pocket-like structure (Figure 13) that promotes the
geometrical specificity of ligands to the detriment of other types of interactions. This site is
defined by the following amino acids: LEU87, LEU88, LYS90, MET92, LEU121, THR122,
ILE131, TYR 132, PHE228, PRO230, PHE233, LEU300, ILE304, GLY307, THR311, LEU376,
HIS377, SER378, PHE380, SER507, TYR401, SER507, MET508.
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  11 of 28 
 
 
 
Figure 13. (A) Docked position of cocrystal (blue) to sterol 14α‐demethylase from Candida albicans (PDB 
id:5FSA) together with (B) the 2D interaction diagram (ball‐stick—cocrystal) and residues forming the 
binding site. HB is indicated by green dashed line. The red residues are involved in hydrophobic inter‐
actions. 
The FUM coformer interacts with sterol 14α‐demethylase through hydrogen bonds 
with the TYR118, HIS377, and SER378 residues through oxygen atoms, while hydropho‐
bic interactions are formed with the LEU121, LEU376, and MET508 residues. KTZ forms 
a single hydrogen bond with TYR64 through its terminal oxygen atom, and it is involved 
in hydrophobic interactions with the following residues: LEU121, THR122, ILE131, TYR 
132,  PHE228,  PHE233,  LEU300,  ILE304,  GLY307,  THR311,  LEU376,  HIS377,  SER378, 
PHE380, SER507, MET508. The KTZ‐FUM cocrystal exhibits the same hydrogen bond 
interaction as KTZ (with TYR64) and additionally forms hydrophobic interactions with 
several  other  residues,  including  LEU87,  LEU88,  LYS90,  MET92,  PRO230,  TYR401, 
SER507, in addition to the above listed for KTZ. 
Reactivity Descriptors Based on DFT 
The parameters describing a compound’s reactivity, namely ionization potential (I), 
electron aﬃnity (A), the HOMO‐LUMO band gap (HLG), global hardness (η), global 
softness (σ), electronegativity (χ), chemical potential (µ), and the global electrophilicity 
index (ω), were also calculated for the KTZ, FUM, cocrystal, and original ligand, with 
results listed in Table 8. 
Table 8. Quantum chemical reactivity descriptors obtained on the optimized geometries of the se‐
lected ligands by Density Functional Theory calculations in gas phase at B3LYP/6‐311+G(2d,p) 
(KTZ, FUM) or B3LYP/6‐311+G(d,p) (cocrystal, original) level of theory. 
eV  FUM  KTZ  Cocrystal  Original 
EHOMO − 8.018 − 5.542 − 5.554 − 5.760 
ELUMO − 2.540 − 1.488 − 2.012 − 1.160 
I  8.018  5.542  5.554  5.760 
A  2.540  1.488  2.012  1.160 
HLG  5.478  4.053  3.542  4.600 
η  2.739  2.027  1.771  2.300 
σ  0.365  0.493  0.565  0.435 
χ  5.279  3.515  3.783  3.460 
µ − 5.279 − 3.515 − 3.783 − 3.460 
ω  5.088  3.048  4.041  2.602 
I—ionization   potential;  A—electron   aﬃnity;  HLG—HOMO ‐LUMO  gap; η —global   hardness; 
σ—global  softness; χ—electronegativity;  µ—chemical  potential; ω—global  electrophilicity index. 
Figure 13. (A) Docked position of cocrystal (blue) to sterol 14α-demethylase from Candida albicans
(PDB id:5FSA) together with ( B) the 2D interaction diagram (ball-stick—cocrystal) and residues
forming the binding site. HB is indicated by green dashed line. The red residues are involved in
hydrophobic interactions.
The FUM coformer interacts with sterol 14α-demethylase through hydrogen bonds
with the TYR118, HIS377, and SER378 residues through oxygen atoms, while hydrophobic
interactions are formed with the LEU121, LEU376, and MET508 residues. KTZ forms a
single hydrogen bond with TYR64 through its terminal oxygen atom, and it is involved in
hydrophobic interactions with the following residues: LEU121, THR122, ILE131, TYR 132,
PHE228, PHE233, LEU300, ILE304, GLY307, THR311, LEU376, HIS377, SER378, PHE380,
SER507, MET508. The KTZ-FUM cocrystal exhibits the same hydrogen bond interaction
as KTZ (with TYR64) and additionally forms hydrophobic interactions with several other
residues, including LEU87, LEU88, LYS90, MET92, PRO230, TYR401, SER507, in addition
to the above listed for KTZ.
Reactivity Descriptors Based on DFT
The parameters describing a compound’s reactivity, namely ionization potential (I),
electron affinity (A), the HOMO-LUMO band gap (HLG), global hardness ( η), global
softness (σ), electronegativity (χ), chemical potential ( µ), and the global electrophilicity
Int. J. Mol. Sci. 2024, 25, 13346 12 of 28
index (ω), were also calculated for the KTZ, FUM, cocrystal, and original ligand, with
results listed in Table 8.
Table 8. Quantum chemical reactivity descriptors obtained on the optimized geometries of the
selected ligands by Density Functional Theory calculations in gas phase at B3LYP/6-311+G(2d,p)
(KTZ, FUM) or B3LYP/6-311+G(d,p) (cocrystal, original) level of theory.
eV FUM KTZ Cocrystal Original
EHOMO −8.018 −5.542 −5.554 −5.760
ELUMO −2.540 −1.488 −2.012 −1.160
I 8.018 5.542 5.554 5.760
A 2.540 1.488 2.012 1.160
HLG 5.478 4.053 3.542 4.600
η 2.739 2.027 1.771 2.300
σ 0.365 0.493 0.565 0.435
χ 5.279 3.515 3.783 3.460
µ −5.279 −3.515 −3.783 −3.460
ω 5.088 3.048 4.041 2.602
I—ionization potential; A—electron affinity; HLG—HOMO-LUMO gap; η—global hardness; σ—global softness;
χ—electronegativity; µ—chemical potential; ω—global electrophilicity index.
Based on the HLG values in Table 8, KTZ is more reactive than posaconazole, the
original antifungal in the complex with sterol 14 α-demethylase. Its reactivity increases
further in its cocrystal form, where the cocrystal has an HLG of 3.54 eV , indicating a shift
from being more stable than the original ligand to being more reactive. The HLG differ-
ence between the cocrystal and posaconazole is 1 eV . FUM is the most stable compound
among the four evaluated. The obtained HLG values of 3.54 eV and higher suggest that
all compounds are stable. The electrophilicity index, which quantitatively measures a
system’s ability to accept electrons, increases from posaconazole to FUM, indicating that
posaconazole is less inclined to accept electrons, while FUM is more receptive to accept
electrons from its environment. Additionally, KTZ’s electron-accepting capacity increases
when in cocrystal form compared to its pure form.
3. Discussion
The focus for successful pharmaceutical drug development lies in the improvement of
the physicochemical and pharmacokinetic properties of the API without compromising
its pharmacological activity. Our previously formulated cocrystal between the antifungal
BCS class II drug Ketoconazole and Fumaric acid (denoted KTZ-FUM, Figure 14) by crystal
engineering resulted in an enhancement of the aqueous solubility (i.e., a 100-fold increase)
and stability both in solid form and suspension as compared to the parent drug [21].
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  12 of 28 
 
 
Based on the HLG values in Table 8, KTZ is more reactive than posaconazole, the 
original antifungal in the complex with sterol 14α‐demethylase. Its reactivity increases 
further in its cocrystal form, where the cocrystal has an HLG of 3.54 eV, indicating a shift 
from being more stable than the original ligand to being more reactive. The HLG diﬀer‐
ence between the cocrystal and posaconazole is 1 eV. FUM is the most stable compound 
among the four evaluated. The obtained HLG values of 3.54 eV and higher suggest that 
all compounds are stable. The electrophilicity index, which quantitatively measures a 
system’s ability to accept electrons, increases from posaconazole to FUM, indicating that 
posaconazole is less inclined to accept electrons, while FUM is more receptive to accept 
electrons from its environment. Additionally, KTZ’s electron‐accepting capacity increas‐
es when in cocrystal form compared to its pure form. 
3. Discussion 
The focus for successful pharmaceutical drug development lies in the improvement 
of the physicochemical and pharmacokinetic properties of the API without compromis‐
ing its pharmacological activity. Our previously formulated cocrystal between the anti‐
fungal BCS class II drug Ketoconazole and Fumaric acid (denoted KTZ‐FUM, Figure 14) 
by crystal engineering resulted in an enhancement of the aqueous solubility (i.e., a 100‐fold 
increase) and stability both in solid form and suspension as compared to the parent drug 
[21]. 
 
Figure 14. Chemical structure of Ketoconazole (KTZ) (left) and Fumaric acid (FUM) (right). 
The KET‐FUM cocrystal was prepared by two diﬀerent approaches, the traditional 
solution crystallization method by solvent evaporation (i.e., acetone–water 8:2 (V/V) and 
acetone–methanol 1:1 (V/V)) and the versatile mechanochemical synthesis by ball milling, 
which involves the liquid‐assisted grinding route (also known as solvent drop grinding, 
SDG) using drops of methanol. The crystal structure of the KTZ‐FUM cocrystal (YIN‐
WAV code from Cambridge Structural Database [34]) contains one Ketoconazole and one 
Fumaric acid molecule in the asymmetric unit, connected via an O4···H2A−O2A hydro‐
gen bond between the acetyl group of KTZ and one of the hydroxyl groups of FUM. The 
other hydroxyl group of FUM is also involved in a hydrogen bond with the imidazole 
group of another KTZ molecule, O4A−H4A···N1 (Figure 15). The nature of the cocrystal 
form is demonstrated by the H4A atom position (not transfer to N1) determined by sin‐
gle‐crystal X‐ray diﬀraction and conﬁrmed by a few structural characteristics of inter‐
acting functional groups: (i) the C4A−O4 (1.284 Å) are longer bonds than C4A = O3A 
(1.204 Å), being speciﬁc to a neutral carboxylic group and (ii) the 105.69 deg value of the 
endocyclic C1‐N1‐C2 bond angle in the triazole ring of KTZ is speciﬁc to unprotonated 
nitrogen. 
Figure 14. Chemical structure of Ketoconazole (KTZ) (left) and Fumaric acid (FUM) (right).
Int. J. Mol. Sci. 2024, 25, 13346 13 of 28
The KET-FUM cocrystal was prepared by two different approaches, the traditional
solution crystallization method by solvent evaporation (i.e., acetone–water 8:2 (V/V) and
acetone–methanol 1:1 (V/V)) and the versatile mechanochemical synthesis by ball milling,
which involves the liquid-assisted grinding route (also known as solvent drop grinding,
SDG) using drops of methanol. The crystal structure of the KTZ-FUM cocrystal (YINWAV
code from Cambridge Structural Database [34]) contains one Ketoconazole and one Fumaric
acid molecule in the asymmetric unit, connected via an O4···H2A−O2A hydrogen bond
between the acetyl group of KTZ and one of the hydroxyl groups of FUM. The other
hydroxyl group of FUM is also involved in a hydrogen bond with the imidazole group of
another KTZ molecule, O4A−H4A···N1 (Figure 15). The nature of the cocrystal form is
demonstrated by the H4A atom position (not transfer to N1) determined by single-crystal
X-ray diffraction and confirmed by a few structural characteristics of interacting functional
groups: (i) the C4A−O4 (1.284 Å) are longer bonds than C4A = O3A (1.204 Å), being specific
to a neutral carboxylic group and (ii) the 105.69 deg value of the endocyclic C1-N1-C2 bond
angle in the triazole ring of KTZ is specific to unprotonated nitrogen.
Int. J. Mol. Sci. 2024, 25, x FOR PEER REVIEW  13 of 28 
 
 
 
Figure 15. The four‐member circuit network of KTZ‐FUM cocrystal. 
The stability of the cocrystal in our previous study was highlighted both in solution 
and solid state by (i) slurry experiments carried out in water and ethanol for at least 1 
week, and (ii) accelerated testing, performed under storage conditions of 40 ± 2 °C/75 ± 
5% RH for at least 4 months. The cocrystal dissociation to free KTZ form was not de‐
tected. Aiming to develop a rational and stable solid dosage form, we also reported its 
solid‐state compatibility with acceptable pharmaceutical excipients in binary mixtures as 
part  of  the  pre‐formulation  stage  [35].  The  results  showed  full  compatibility  of  the 
KTZ‐FUM with various excipients (i.e., hydroxypropyl methylcellulose K4M, lactose 
monohydrate, corn starch, silicon dioxide, and talc), thereby proving its capability to be 
marketed as a stable pharmaceutical cocrystal product. 
3.1. Controlled Cocrystallization Process by Cooling 
Developing pharmaceutical cocrystals implies a complex process that follows sev‐
eral distinctive phases within a regulatory framework established by the FDA [36]. A 
crucial part of the cocrystallization research is attributed to the nucleation and growth of 
cocrystals as a result of combining the coformers in a solution. In the cocrystallization 
process by cooling, the dissolution of both coformers is achieved by heating the solvent to 
a high temperature, followed by cooling, according to an established temperature proﬁle. 
The solubility of the coformers decreases with decreasing solution temperature. This 
creates the supersaturation necessary for the occurrence of the nucleation process and 
crystal growth. Nucleation takes place only after the coformers solution has surpassed 
the metastable zone, deﬁned as the zone between the concentration of solubility and the 
concentration of detection of the ﬁrst nuclei (supersolubility) [37]. The metastable zone 
width—MSZW—is   the  temperature  diﬀerence  between  the  spontaneous  nucleation 
temperature and the saturation one, and is aﬀected by several variables, such as the 
cooling rate, stirring rate, or impurities [38]. Thus, deﬁning the width of the metastable 
region for a compound is of utmost importance for the design and operation process at 
industrial scale. Scale‐up development of the cocrystallization process is challenging be‐
cause it must ensure reproducibility, purity, morphology and particle size, and ﬁnally a 
good yield of the product [39]. Another focus in cocrystals synthesis must be given to the 
screening stage for the identiﬁcation of polymorphic forms. These forms can possess 
varying physicochemical properties, which can negatively aﬀect the cocrystal’s perfor‐
mance [40]. 
Considering all mentioned above, a controlled cocrystallization process by cooling 
for the KTZ‐FUM cocrystal was developed to determine the MSZW. Therefore, we es‐
tablished the optimal cocrystallization parameters to eﬃciently yield the cocrystal as a 
pure and single phase. Moreover, its reproducibility and stability in solution were also 
demonstrated. Among the seven tested solvent systems (e.g., acetone–water mixtures, 
ethanol–water 8:2 (V/V), 2‐propanol) and a range of concentrations (10–160 mg mL−1), the 
measurement of MSZW for the optimal nucleation process was achieved just in the ace‐
tone–water 4:6 (V/V) mixture and ethanol. The highest cocrystallization yield was ob‐
Figure 15. The four-member circuit network of KTZ-FUM cocrystal.
The stability of the cocrystal in our previous study was highlighted both in solution
and solid state by (i) slurry experiments carried out in water and ethanol for at least 1 week,
and (ii) accelerated testing, performed under storage conditions of 40 ± 2 ◦C/75 ± 5%
RH for at least 4 months. The cocrystal dissociation to free KTZ form was not detected.
Aiming to develop a rational and stable solid dosage form, we also reported its solid-state
compatibility with acceptable pharmaceutical excipients in binary mixtures as part of the
pre-formulation stage [35]. The results showed full compatibility of the KTZ-FUM with
various excipients (i.e., hydroxypropyl methylcellulose K4M, lactose monohydrate, corn
starch, silicon dioxide, and talc), thereby proving its capability to be marketed as a stable
pharmaceutical cocrystal product.
3.1. Controlled Cocrystallization Process by Cooling
Developing pharmaceutical cocrystals implies a complex process that follows several
distinctive phases within a regulatory framework established by the FDA [36]. A crucial
part of the cocrystallization research is attributed to the nucleation and growth of cocrystals
as a result of combining the coformers in a solution. In the cocrystallization process by
cooling, the dissolution of both coformers is achieved by heating the solvent to a high
temperature, followed by cooling, according to an established temperature profile. The
solubility of the coformers decreases with decreasing solution temperature. This creates the
supersaturation necessary for the occurrence of the nucleation process and crystal growth.
Nucleation takes place only after the coformers solution has surpassed the metastable
zone, defined as the zone between the concentration of solubility and the concentration of
detection of the first nuclei (supersolubility) [37]. The metastable zone width—MSZW—
is the temperature difference between the spontaneous nucleation temperature and the
saturation one, and is affected by several variables, such as the cooling rate, stirring rate,
or impurities [ 38]. Thus, defining the width of the metastable region for a compound
Int. J. Mol. Sci. 2024, 25, 13346 14 of 28
is of utmost importance for the design and operation process at industrial scale. Scale-
up development of the cocrystallization process is challenging because it must ensure
reproducibility, purity, morphology and particle size, and finally a good yield of the
product [39]. Another focus in cocrystals synthesis must be given to the screening stage for
the identification of polymorphic forms. These forms can possess varying physicochemical
properties, which can negatively affect the cocrystal’s performance [40].
Considering all mentioned above, a controlled cocrystallization process by cooling for
the KTZ-FUM cocrystal was developed to determine the MSZW. Therefore, we established
the optimal cocrystallization parameters to efficiently yield the cocrystal as a pure and
single phase. Moreover, its reproducibility and stability in solution were also demonstrated.
Among the seven tested solvent systems (e.g., acetone–water mixtures, ethanol–water 8:2
(V/V), 2-propanol) and a range of concentrations (10–160 mg mL−1), the measurement of
MSZW for the optimal nucleation process was achieved just in the acetone–water 4:6 (V/V)
mixture and ethanol. The highest cocrystallization yield was obtained in the case of a KTZ
concentration of 100 mg mL−1 in the acetone–water 4:6 (V/V) solvent mixture.
3.2. Scale-Up Experiments of the Ketoconazol-Fumaric Acid Cocrystal
Up-scaling the production of pharmaceutical cocrystalline materials from laboratory
small-scale screening (miligrams) and laboratory up-scaling (grams) to marketed drug
products (kilo to multikilo) involves well-designed and established processes in order to
provide high-purity cocrystals with high yields.
Two different laboratory up-scaling approaches, cocrystallization by cooling in solu-
tion and mechanochemistry synthesis (i.e., SDG), were employed for the KTZ-FUM cocrys-
tal production at the scale of gram-size quantities according to cocrystallization parameters
obtained within the MSZW. Solvent drop grinding is a commonly used, eco-friendly, and
economically feasible approach for faster cocrystals production at large scale [ 41]. This
method also enhances yields and accelerates reaction rates compared to solution-based
procedures, and does not imply additional purification steps, e.g., liquid extraction.
Both methods successfully enabled the production of the pure KTZ-FUM cocrys-
tal solid form to 1 g batch sizes with high yields, and without traces of residual pure
components.
3.3. Biological Assays
3.3.1. Cell Viability
In both cell lines, the dermal fibroblasts and hepatocarcinoma cells, KTZ-FUM was
better tolerated than KTZ, showing improved biocompatibility in vitro. Fumaric acid in-
hibited cell viability. Liver toxicity of Fumaric acid esters (FAEs) was previously reported
in psoriatic patients treated with these drugs and was not related to alcoholic abuse [42].
Fumaric acid esters were shown to inhibit inflammation by decreasing the differentiation of
dendritic cells [43] and to inhibit neo angiogenesis by altering the metabolism of endothelial
cells [44] through increased glycolysis and decreased oxidative metabolism, without com-
promising the cell viability even at a 100 µM concentration of dimethyl fumarate. Similar
metabolic effects were found in MDA-MB 231 breast cancer cells and HGF-human gingival
fibroblasts, but not in HeLa cancer cells [45]. In the HepG2 cell line, our viability results are
similar to those obtained by others [46], using different FAEs.
3.3.2. Oxidative Stress
Exposure of the cells to KTZ induced a lower MDA, as previously reported by us [47],
and this effect was increased in the case of KTZ-FUM and decreased for Fumaric acid
exposure. The antioxidant effects induced by Fumaric acid esters were shown to be dose-
dependent for concentrations ranging between 0.1 mM and 3 mM on in vitro HepG2
cultures. The main antioxidant mechanism was due to the activation of the NRF2 signaling
pathway [45]. The concentration of 6 µM used for the current experiment was much
smaller, not enough to induce an antioxidant effect. However, the cocrystal showed
Int. J. Mol. Sci. 2024, 25, 13346 15 of 28
improved antioxidant ability, when compared to the parent drug, suggesting a synergic
effect of the KTZ and Fumaric acid even at this low concentration that might be beneficial
for the therapy.
3.3.3. Pharmaco-Dynamic Profile
Improving bioavailability has been the target of many new KTZ formulations, such
as KTZ-loaded lipid nano formulations, solid lipid nanoparticles, and nanostructured
lipid carriers. Even though Fumaric acid is a poorly water-soluble acid on its own, it may
be of use with KTZ in granule form to promote a controlled release profile [ 48]. Studies
on these formulations reported increased in vitro antifungal efficiency against Candida
albicans and improved bioavailability in comparison to control KTZ suspensions when
administered to Wistar rats [49]. With regards to efficacy, KTZ-loaded poly-lactic acid (PLA)
nanoparticles were more effective against Candida species and dermatophytes than the
free drug in vitro [50]. Hyaluronic acid-based gels with KTZ-loaded nanostructured lipid
carriers showed improved drug diffusion and antifungal activity in vitro and ex vivo [51].
In a previous article, we demonstrated that the cocrystal obtained by using p-amino
benzoic acid (PABA) and Ketoconazole (KTZ-PABA) showed an improved relative bioavail-
ability of 6.72 over the KTZ in Wistar rats [47]. The data showed that the increased solubility
of the KTZ-PABA led to a higher plasma concentration of 66.39 µg mL−1 at 1 h after the
oral administration of 20 mg kg−1 bw. Although the maximum plasma concentration of the
KTZ-PABA was higher than that of KTZ-FUM (52.21 µg mL−1), the relative bioavailability
of the KTZ-FUM compared to KTZ was better. This is probably because of the increased
solubility of the KTZ-FUM compared to the KTZ-PABA cocrystal and the more controlled
release of the KTZ due to the presence of the Fumaric acid.
3.3.4. Hepatotoxicity
Hepatotoxicity is one of the severe adverse effects of systemic KTZ-based therapy.
In biopsy samples from 14 patients suffering from hepatic injury after KTZ treatment,
centrilobular cholestasis or necrosis were reported, the latter being associated with primarily
monocytic inflammatory infiltration [52]. Biochemically and histologically, hepatocellular
necrosis is the most common type of hepatic injury observed in humans across studies [53].
In a study that compared the degree of hepatic injury in 66 Sprague Dawley rats
that received oral antifungal agents (Fluconazole, Ketoconazole, Itraconazole, Terbinafine,
and Griseofulvin), no macroscopic hepatic changes were observed in any group, whereas
biochemical assays revealed that KTZ led to the highest ALT and AST levels. There was,
however, a poor correlation between serum enzyme levels and histological examination,
the latter revealing that fluconazole treatment caused the most severe damage compared to
all groups [54].
In our experiments, the dynamics of the ALT and AST levels showed the highest
increase in the AST/ALT ratio at 8 h, followed by a decrease below the control level at
7 days. The biochemical alterations were not accompanied by histological changes.
KTZ toxicity has also been linked to oxidative stress. In addition to lanosterol 14-α-
demethylase inhibition, it has been suggested that fungicidal imidazoles owe a share of
their effects to the generation of reactive oxygen species (ROS) in target pathogens [55–57].
Furthermore, in vitro murine [58] and human cell [59] study models demonstrated that,
when exposed to Ketoconazole, healthy tissue is subject to oxidative stress, mitochondrial
disfunction, and apoptosis. In a study on TM4 mouse Sertoli cells, pre-treatment with
N-acetylcysteine mitigated cytokine production and ROS accumulation during azole treat-
ment, and rescued the cells from apoptosis. This indicated that azole-induced cytotoxicity
may be ROS-dependent [60]. For the investigation of KTZ-induced oxidative stress and
pro-inflammatory activity, others have used different biomarkers, such as lactate dehy-
drogenase (LDH), superoxide dismutase (SOD), catalase (CAT), glutathione S-transferase
(GST), malonealdehyde (MAD), and ascorbate peroxidase (APX) [61–63].
Int. J. Mol. Sci. 2024, 25, 13346 16 of 28
Studies investigating how to offset the KTZ-induced hepatotoxicity have shown that
dietary supplements, such as sesame oil [64] and gentiana lutea [65], and hormones like
melatonin [63] may reduce the hepatotoxic effects of KTZ as a result of their respective
antioxidant effects.
In our experimental setting, the increase in MDA immediately after the oral adminis-
tration was not significant, and it was followed by normalization within 24 h. This was
combined with insignificant changes in the inflammatory cytokine TNFα.
Others showed, in a study on Wistar rats, that Fumaric acid co-administered with
cadmium at hepatotoxic doses demonstrated a protective effect by anti-inflammatory and
antioxidative mechanisms [66]. Rat hepatocytes showed increased DNA synthesis follow-
ing Fumaric acid administration despite mitomycin C and aflatoxin B1 intoxication [67].
Liver and kidney damage incurred by Mitomycin C was also shown to decrease with con-
current administration of Fumaric acid [68]. Initial studies on Fumaric acid have affirmed
its low toxicity in humans, with no evidence of adverse effects recorded for 75 subjects that
received 500 mg daily for one year [69].
3.3.5. Hematology and Biochemistry Measurements
Some of the less common reported side effects ( ≤1%) in humans during KTZ oral
administration were thrombocytopenia [70], leukopenia, hemolytic anemia, and dyslipi-
demia [71]. In our experimental setting, the oral KTZ-FUM unique dose induced a tempo-
rary red blood cell count increase in the first 72 h and a slight thrombocytosis.
3.3.6. Epicutaneous Sensitization Test
When used as a local treatment, KTZ may reduce inflammation. Applied topically on
the skin of guinea pigs exposed to living or killedStaphilococcus aureus, KTZ exhibited a sim-
ilar or improved anti-inflammatory efficacy in comparison to hydrocortisone acetate [72].
Similar results were obtained in a double-blind study investigating seborrheic dermatitis
treatment in humans, which did not find statistically significant differences in symptom
alleviation between hydrocortisone and KTZ treatments [73]. This suggested that the anti-
inflammatory activity is part of the therapeutic benefit of the drug. One of the mechanisms
by which KTZ directly decreases inflammation was proven to be lypooxygenase-5 inhibi-
tion, thus limiting the biosynthesis of leukotrienes [74]. KTZ can also reduce prostaglandin
production via COX-2 down-regulation, a property which was exploited to trigger apopto-
sis via mitophagy in neoplasms such as epidermoid [75] and hepatocellular carcinoma [76],
and to reduce drug resistance in human chronic myelogenous leukemia cells [77]. In pre-
vious studies, we found increased COX2 levels in vitro on human dermal fibroblasts and
endothelial cells [47]. The same effect was found, although reduced, following local ear
application on mouse ears, combined with increased anti-inflammatory cytokine IL10 [78].
When the cocrystal KTZ-PABA was used, the KTZ-induced increase in COX2 was decreased
both in vitro and in vivo [78].
In tests for the evaluation of the skin sensitization potential by murine local lymph
node assay and the guinea pig maximization test, FUM gave negative results [79], although
its esters are contact allergens [80]. Topical KTZ use is linked to irritant contact dermati-
tis and potential sensitization [ 81], with rare reports of allergic [ 82] and, exceptionally,
photoallergic contact dermatitis [83].
In our experiment, the KTZ-FUM and KTZ or Fumaric acid did not induce any allergic
reactions following local applications. Moreover, the ear tissue showed a slight decrease in
IL1α and IL 6 pro-inflammatory cytokines, indicating a reduced anti-inflammatory effect,
as previously reported by us for the KTZ-PABA cocrystal [78] and others [63].
3.4. Molecular Docking Study
According to a former study, the in vitro antifungal activity of the KTZ-FUM cocrystal
was evaluated on various fungal species (e.g., Candida albicans, Trichophyton rubrum) and
revealed that KTZ therapeutic activity was not altered due to its formulation with the FUM
Int. J. Mol. Sci. 2024, 25, 13346 17 of 28
coformer [84]. Considering these data, KTZ, FUM, cocrystal, and posaconazole (original
ligand) were further evaluated in silico to determine the influence of FUM on KTZ’s affinity
for the sterol 14-α demethylase (CYP51) enzyme from the pathogenic yeast Candida albicans
(PDB id: 5FSA) and its binding energy.
Autodock Vina [85] is an automated routine used to predict ligand–receptor interac-
tions. It performs a detailed scan across all available degrees of freedom as torsion angles
of the ligand combine with a rapid grid-based energy evaluation. Through the application
of a search algorithm and an empirical free energy scoring function, the routine refines
the many possible docking conformations to identify the most probable one—the one
with the lowest binding energy between the receptor and the ligand. As the algorithm is
non-deterministic, each run generates stochastic results. Thus, for each ligand–receptor pair
across the four systems (four ligands and one receptor), 10 binding modes were generated
per run. The exhaustiveness parameter was set at its default value of 8. The code was
run 20 times, producing 200 docking conformations for each system. Consistent with the
methodology outlined in our previous work [86,87], this sample size was deemed enough
to characterize the ligand–sterol 14α-demethylase interactions from both the perspective of
predicted binding energy and geometrical specificity.
Among all studied systems, the KTZ-FUM cocrystal interacted more effectively with
the enzyme, as the FUM coformer enhanced its binding affinity. This enhancement of KTZ
affinity has been previously observed with p-hydroxy benzoic acid [88].
The highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular
orbital (LUMO) of a molecule are key indicators of its chemical reactivity and stability.
The calculation of their energies is essential for understanding intermolecular interactions.
The HOMO energy reflects a molecule’s electron-donating capability, while the LUMO
energy represents its electron-accepting potential. According to Koopmens theory, the first
ionization energy of a molecule is equal to the negative value of its HOMO energy [ 89].
Building on this theory, several parameters have been defined over time to provide a more
detailed characterization of a compound’s reactivity, including ionization potential (I), elec-
tron affinity (A), the HOMO-LUMO band gap (HLG), global hardness (η), global softness
(σ) [90], electronegativity (χ) [91], chemical potential ( µ), and the global electrophilicity
index (ω) [92,93]. The HLG describes the charge transfer interactions between a molecule
and its surroundings, and its value represents the energy required to remove an electron
from HOMO. A smaller HLG indicates a faster reaction and is a key reactivity descriptor
of molecular stability. More reactive molecules exhibit smaller HLG values and higher
softness values.
The molecular docking study reveals that KTZ, FUM, and the cocrystal interact with
the sterol 14α-demethylase enzyme from C. albicans through a combination of hydrogen
bonds and hydrophobic interactions. Moreover, the cocrystal exhibited greater chemical
reactivity than the original ligand, posaconazole, as indicated by HLG and increased
softness. Additionally, KTZ’s electron-accepting capacity increases in its cocrystal form,
thus making it more reactive than the original ligand.
4. Materials and Methods
4.1. Materials and Reagents
Commercial form Ketoconazole was purchased from Melone Pharmaceutical Co., Ltd.
(Dalian, China), and Fumaric acid from Merck KGaA, Darmstadt, Germany. Reagent-grade
solvents ethanol, acetone, 2-propanol, dimethyl sulfoxide (cell culture grade) (Merck KGaA,
Darmstadt, Germany), and ultrapure water (prepared by Milli-Q Ultrapure purification
system, East Lyme, CT, USA) were used. Polyvinylpyrrolidone K30 (PVP K30), used as a
suspending agent, was purchased from Tokyo Chemical Industry Co., Ltd., Tokyo, Japan.
Ethyl acetate used for KTZ-FUM extraction from serum samples from Chimopar Trading
SRL (Bucharest, Romania); HPLC-grade acetonitrile from VWR Chemicals (Rosny-sous-
Bois, France) and formic acid from Crystal R Chim SRL (Bucharest, Romania). The solids
and solvents were used as received without any further purification.
Int. J. Mol. Sci. 2024, 25, 13346 18 of 28
For in vitro and in vivo analysis, the following were employed: dermal fibroblasts (BJ-
ATCC CRL-2522™) and hepatocarcinoma cells (HepG2-HB-8065, ATCC, Gaithersburg, MD,
USA), Dulbecco’s modified Eagle medium (DMEM), fetal calf serum (FCS), gentamycin,
amphotericin from Biochrom AG, Berlin, Germany; dimethylsulfoxide (DMSO) cell culture
grade (Merck KGaA, Darmstadt, Germany); MTS assay—CellTiter 96 ® AQueous Non-
Radioactive Cell Proliferation Assay (MTS, Promega Corporation, Madison, WI, USA);
malondialdehyde, Petri dishes (TPP , Transadingen, Switzerland); hematoxylin−eosin (HE)
from Sigma-Aldrich Co, St. Louis, MO, USA; vacutainers (Vacuette Z serum clot activator
tubes; Greiner Bio-One Ltd., Stonehouse, UK); Aspartate Aminotransferase (AST/GOT),
Alanine Aminotransferase (ALT/GPT) Activity Assay Kits, Glucose (Glu) Colorimetric
Assay Kit, Free Cholesterol (FC) Colorimetric Assay Kit and respectively Malondialdehyde
Colorimetric Assay Kit (TBA Method) provided by ElabScience (Wuhan, China); soluble tu-
mor necrosis factor alpha (TNF-α, Quantikine ELISA Immunoassay kit, R&D Systems, Inc.,
Minneapolis, MN, USA); vitamin A and dinitrochlorobenzene (Sigma-Aldrich, St. Louis,
MO, USA); Freund’s complete adjuvant (Thermo Scientific™, Waltham, MA, USA); stan-
dard food for lab animals; rats were purchased from Cantacuzino Institute, Bucharest,
Romania.
4.2. Cocrystallization Process by Cooling for Metastable Zone Width (MSZW) Determination
In 1.5 mL glass vials, known amounts of Ketoconazole and Fumaric acid in 1:1 molar
ratio, and determined volume of solvent (0.5 or 1 mL) were added. A wide range of
concentrations between 10 and 160 mg mL−1 and 7 solvent systems were tested: acetone–
water mixture as 1:1, 9:1, and 4:6 (V/V) ratios, ethanol, ethanol–water 8:2 (V/V), 2-propanol,
and 2-propanol–water 8:2 (V/V). The obtained suspensions were subjected to a controlled
heating–cooling cycle performed on a magnetic stirrer (Heidolph, Scwabach, Germany).
During the experiment, the vials were kept in a glycerin bath. The complete dissolution was
reached under a controlled 1–3 ◦C min−1 heating rate and magnetic stirring; the solutions
were then maintained at dissolution temperature for 5 min, followed by slow, controlled
cooling, with 1–3 ◦C min−1 cooling rate to 10 ◦C, while the precipitation was completed.
The solvents were removed by evaporation at room temperature until the solid materials
were completely dry and were analyzed by PXRD.
4.3. Scale-Up Experiments of the Ketoconazole-Fumaric Acid Cocrystal
4.3.1. Cocrystallization by Cooling in Solution
The scaling experiments by cooling cocrystallization method in solution were per-
formed with the synthesizer process station Eyela PPS-CTRL 1 (Tokyo Rikakikai Co., Ltd.,
Tokyo, Japan), and denoted SU-E1 and SU-E2. The Eyela platform is equipped with 5 re-
action vessels and enables individual setting of synthesis parameters, e.g., temperature,
stirring. The reaction slurry mixtures composed of 1 g Ketoconazole, 0.218 g Fumaric acid,
and the solvent, namely acetone–water mixture 4:6 (V/V) 13 mL and ethanol 20 mL, were
homogenized by magnetically stirring at r.t. for 10 min and 400 rpm. The suspensions were
heated to 65 ◦C under stirring (1000 rpm) with 2 ◦C min−1 heating rate until the solids
fully dissolved. After the heating was stopped, the solutions were slowly cooled to 5 ◦C by
3 ◦C min−1 cooling rate. The solutions were kept at 5 ◦C for 24 h and then decanted. The
residual solvents were removed by evaporation at room temperature until the materials
were completely dry.
4.3.2. Mechanochemical Synthesis
The mechanochemical scale-up experiments were carried out using a MM400 vibration
ball milling (Retsch, Haan, Germany) and 5 mL stainless steel reaction jar by solvent drop
grinding syntheses and are denoted SU-SDG1 and SU-SDG2. Equimolar quantities of
pure components consisting of 1 g Ketoconazol and 0.218 g Fumaric acid were weighted
followed by addition of 250 µL of solvent, i.e., acetone–water mixture 4:6 (V/V) or ethanol
into the jar mill, which contained one stainless steel ball. The reaction mixtures were milled
Int. J. Mol. Sci. 2024, 25, 13346 19 of 28
for 90 min at a frequency of 30 Hz. The resulting white powders were distributed on filter
paper and air-dried.
4.4. Powder X-Ray Diffraction (PXRD) Characterization Method
KTZ-FUM cocrystal identity was confirmed by PXRD technique on a Bruker D8
Advance powder diffractometer using Cu K α1 radiation ( λ = 1.54056 Å). The θ−2θ
Bragg −Brentano configuration geometry and incident beam Ge (111) monochromator
were used. The measurements were performed at room temperature in the 3−40◦ range in
steps of 0.02◦.
4.5. In Vitro Assays
Dermal fibroblasts (BJ-ATCC CRL-2522™) and hepatocarcinoma cells (HepG2-HB-
8065, ATCC, Gaithersburg, MD, USA) were employed. Cell culture medium used was
Dulbecco modified Eagle medium (DMEM) supplemented with 5% FCS-fetal calf serum,
50 µg mL−1 gentamycin, and 5 ng mL −1 amphotericin, all from Biochrom AG (Berlin,
Germany). Medium was changed twice a week. For all experiments, a medium with 2%
FCS was used. To solve KTZ and KTZ-FUM in medium, substances were first solved in
dimethyl sulfoxide at a concentration of 1 mg mL−1 to make a stock solution, and then the
stock solutions were used to make the final concentrations in culture media immediately
before the treatment. The final concentration of DMSO in the solutions added to the cells
was lower than 0.05%, without negative viability effects [36].
4.5.1. Cell Viability
Viability was measured using the MTS assay CellTiter 96® AQueous Non-Radioactive
Cell Proliferation Assay from (Promega Corporation, Madison, WI, USA), as indicated
by the producer. Cells (BJ and HepG2) were cultivated on 96 well plaques at a density of
104/well, accommodated in standard conditions for 24 h, then exposed to a fresh medium
containing different KTZ, KTZ-FUM, and FUM concentrations for 24 h (range 0.01–100µM).
Negative controls were treated with medium. Viability was measured through colorimetry,
using an ELISA plate reader (Tecan, Männedorf, Switzerland) at 540 nm. All experiments
were performed in triplicate. Results are presented as % of untreated control, and the dose
that caused a viability decrease below 70% was considered toxic. Inhibitory concentration
(IC50) was calculated.
4.5.2. Oxidative Stress-Induced Damage
Oxidative stress-induced damage was assessed in vitro by malondialdehyde (MDA)
measurement from cell lysates. Cells (BJ or HepG2) were cultured on Petri dishes at a
density of 105/cm2 (TPP , Transadingen, Switzerland) for 24 h, then cells were exposed to
6 µM of each substance (KTZ, KTZ-FUM, Fumaric acid, respectively) for additional 24 h;
afterwards, cells were washed and collected by scraping on ice. Cell lysates were then
prepared as described [94]. The concentration of 6 µM was chosen to mimic the clinical
scenario [47]. According to the reports by others, the plasma concentration of Ketoconazole
after a therapeutic oral dose of 200 mg KTZ in healthy humans was 5.85 µM [95,96].
4.6. In Vivo Assays
4.6.1. Experimental Design
The animal study protocol was approved by the Ethics Committee of the Univer-
sity of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca and the Veterinary Health
Directorate, Romania (protocol code 329/17 08 2022).
Adult female Wistar rats, 3 months old (200 g body weight), were kept in standard
cages type II, 5 animals/cage, in constant conditions of humidity (65%), temperature
(21 ◦C), and day/night cycles of 12 h, fed with standard food (Cantacuzino Institute,
Bucharest, Romania) and water ad libitum. The animals were randomly divided into
3 groups: controls—baseline, no therapy (3 animals), KTZ (33 animals), and KTZ-FUM
Int. J. Mol. Sci. 2024, 25, 13346 20 of 28
(33 animals). Animals were administered through gavage a unique oral dose of 20 mg kg−1
body weight of KTZ or KTZ-FUM suspended in PVP K30 0.5% aqueous solution at a
final concentration of KTZ—4 mg mL−1 as previously described [47]. The dose calculated
according to Nair AB et al. corresponds to the clinically recommended oral dose of KTZ
in humans of 200 mg/day [97]. The lab animals (3 animals/time interval) were humanely
sacrificed at different time points following oral administration at 0.033 h, 0.083 h, 0.25 h,
1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 48 h, and 7 days [98]. Blood and liver samples were collected.
4.6.2. Pharmacokinetic Profile
Serum KTZ and KTZ-FUM levels were measured by HPLC-MS. Regarding HPLC-MS
Quantification, serum samples were processed according to the modified protocol described
by Wang et al. [99]. According to this protocol, 0.5 mL of serum was extracted into 3 mL of
ethyl acetate by shaking for 3 min, after which the mixture was centrifuged for 8 min at
4000 rpm. The organic layer, after being transferred to a clean tube, was evaporated at 37◦C
under a stream of nitrogen. The residue was resuspended in 100 µL acetonitrile and then
analyzed using a LC2010 Shimadzu (Shimadzu, Kyoto, Japan) high-performance liquid
chromatograph, equipped with diode array (DAD) and quadrupole mass spectrometer
(MS) detectors.
Chromatographic separation was performed on a Grace Alltima C18 column (100×3 mm,
3 µm), at a temperature of 40 ◦C, using acetonitrile-water mixture 1:1 ( V/V) with 0.1%
formic acid as the mobile phase. The elution was carried out isocratically with 0.4 mL min−1
flow rate. The injected sample volume was 10 µL. The mass spectrometer parameters were
the capillary voltage of 1.5 kV , desolvation temperature of 250◦C, and interface temperature
of 200 ◦C. The positive ionization mode was applied for KTZ mass spectra registration and
negative ionization mode was applied for FUM mass spectra registration. For KTZ-FUM
concentrations determination in the analyzed plasma, standard solutions of KTZ-FUM
were prepared by successive dilutions starting from a concentration of 1 mg mL−1 in the
concentration range of 0.001–0.1 mg mL−1.
KTZ-FUM from serum samples was quantified by external standard method using
a calibration curve. The regression equation was expressed as y = 1 × 109x + 4 × 106 for
KTZ and y = 3 × 106x + 10,660 for FUM. The coefficient of correlation (R2) was about
0.9990 for all. Also, the limit of detection (LOD) and quantification (LOQ) were found to be
1.82 µg mL−1 and 3.61 µg mL−1 for KTZ and 1.664 µg mL−1 and 3.292 µg mL−1 for FUM.
Relative bioavailability (F) of the KTZ-FUM over KTZ, after a unique oral dose, was
calculated using the following formula:
F = AUC KTZ-FUM/AUC KTZ × Dose KTZ/Dose KTZ-FUM, (1)
where AUC represents the area under the curve of serum concentration over time for KTZ,
KTZ-FUM, respectively, determined by using GraphPad software.
4.6.3. Hepatotoxicity Assessment
Liver transaminase activities were measured in the serum of the rats treated with KTZ-
FUM at the same time points, using Aspartate Aminotransferase (AST/GOT) and Alanine
Aminotransferase (ALT/GPT) Activity Assay Kits, respectively, both from ElabScience
(Wuhan, China), as indicated by the manufacturer.
For the histopathological examination, the liver samples collected from the left lateral
lobe and right medial lobe were fixed in 10% buffered neutral formalin, embedded in
paraffin, cut at 4 µm thickness, and stained using the Hematoxylin–Eosin (H&E) staining
method. The slides were examined under a BX51 Olympus microscope, and images
were taken with an Olympus UC 30 digital camera (Olympus, Hamburg, Germany) and
processed using the Olympus Stream Basic program.
Hematology and Biochemistry analyses: Hematology measurements were performed
on freshly collected blood samples, in violet top vacutainers (K3-EDTA, 0.5 mL, Greiner
Bio-One Ltd., Stonehouse, UK), using an automatic hematology Analyzer Mindray BC
Int. J. Mol. Sci. 2024, 25, 13346 21 of 28
6200, seria TW-1B001864, from Mindray, Shenzhen, China. For the biochemistry analysis of
glucose and cholesterol from blood serum samples, the Glucose (Glu) Colorimetric Assay
Kit and Free Cholesterol (FC) Colorimetric Assay Kit (both from ElabScience), respectively,
were employed as indicated by the producer.
4.6.4. Oxidative Stress and Inflammation
For the oxidative stress assessment, the level of malondialdehyde, a marker of lipid
peroxidation, was measured from lysates of liver samples (in vivo) and cells-BJ and HepG2
(in vitro), using the Malondialdehyde Colorimetric Assay Kit (TBA Method) provided
by ElabScience. Tissue sample homogenates (liver and ear) were prepared as previously
described by David et al. [100]. The protein content in tissue homogenates was measured
by Bradford method [101]. Inflammatory reaction was assessed by measurement of the
tumor necrosis factor α (TNFα) in liver samples, using the rat TNFα ELISA kit from EIAAB.
IL1α and β and IL6 measurement from the mice ear lysates were completed by ELISA,
using the respective kits from Quantikine ELISA Immunoassay kit. Tissue homogenate
samples were treated according to manufacturer’s instructions; readings were performed
at 450 nm with correction wavelength set at 540 nm, using an ELISA plate reader (Tecan,
Grödig, Austria).
4.6.5. Mouse Epicutaneous Sensitization Test (MEST)
MEST was performed on BALBc mice (11 weeks old females) [102] purchased from
Cantacuzino Institute (Bucharest, Romania). Mice were kept in constant conditions of
humidity (65%), temperature (21 ◦C), and day/night cycles of 12 h, 5 animals/cage, fed
with standard food (Cantacuzino Institute, Bucharest, Romania) and water ad libitum. Mice
food was supplemented with vitamin A (250 UI g−1) to increase test sensitivity [103,104].
MEST protocol was performed as previously reported [78].
In total, 35 mice were randomly divided into five groups, 7 animals/group: group
1—control–vehicle (alcohol 70%), group 2—KTZ, group 3—KTZ-FUM, group 4—Fumaric
acid, and group 5—dinitrochlorobenzene (DNCB, Sigma-Aldrich, St. Louis, MO, USA). On
day one, under anesthesia, all mice received 30 µL/mouse of Freund’s complete adjuvant
(Thermo Scientific™, Waltham, MA, USA), subcutaneously, in the right flank and the
abdominal fur was carefully shaved, without skin abrasion. Then animals were treated
with 100 µL of locally applied solution (abdominal skin) of each tested substance, in a
concentration of 200 µg mL−1 solved in ethanol 70%, daily for the first 6 days [78,105]. The
left ear thickness of each mouse was measured with an electronic caliper (initial value).
Each mouse was treated with 50 µL/ear of the same solution on the left ear pinnae on day
7—challenge and on day 14—rechallenge. Ear thickness was measured at 24 h and 48 h
after challenge and rechallenge, respectively [102]. Then mice were humanely sacrificed,
under anesthesia, and ears were collected for inflammatory markers (IL1α, IL1β and IL6)
assessment and histopathology.
Calculations were performed using the following formula:
% ear thickness = 100 × (A − B)/B, (2)
where A = ear thickness of the treated ear, B = initial ear thickness.
4.6.6. Histopathology
For histopathological examination, the collected samples (liver and ears) were fixed in
10% buffered neutral formalin, embedded in paraffin, cut at 4 micrometer thickness, and
stained using the Hematoxylin–Eosin (H&E) method. The slides were examined under a
BX51 Olympus microscope, and images were taken with an Olympus UC 30 digital camera
(Olympus, Hamburg, Germany) and processed using the Olympus Stream Basic program.
Int. J. Mol. Sci. 2024, 25, 13346 22 of 28
4.6.7. Statistical Methods
The statistical difference between experimental groups was evaluated by nonpara-
metric Kruskal–Wallis test, followed by Dunns post-test; the statistical significance of the
treatments and time exposure within the experimental groups was tested using two-way
ANOVA, followed by Bonferroni post-tests; results were considered significant forp < 0.05.
For the in vivo pharmaco-dynamic profile of KTZ and KTZ-FUM, the AUC = area under
curve was calculated. Statistical package used for data analysis was Prism version 4.00
for Windows, GraphPad Software, San Diego, CA, USA, www.graphpad.com. For IC 50
calculation of the cell viability in vitro, the AAT Bioquest was used [106].
4.7. Molecular Docking Study Methods
The protein structure of sterol 14-α demethylase (CYP51) from the pathogenic yeast
Candida albicans [PDB id: 5FSA] [107] was obtained from the Protein Data Bank and used
as the receptor in this study. Prior to the building of the ligand–receptor systems, all
water molecules, the original ligand, and other cofactors were removed from the recep-
tor’s structure using Molegro Molecular Viewer 2.5 (Molexus Ivs, a CLC biocompany,
Odder, Denmark). KTZ, FUM, and cocrystal were selected from the .cif file of our previ-
ously obtained structure [21]. KTZ, FUM, cocrystal, and the antifungal drug posaconazole
originally complexed to the protein were selected as ligands. The geometries of all lig-
ands were optimized prior to molecular docking in gas phase by using B3LYP hybrid
exchange-correlation functional [108–111] coupled with 6-311+G(2d,p) (FUM and KTZ) or
6-311+G(d,p) (for cocrystal and original) basis sets as implemented in Gaussian software
16 Rev. C.01/C.02 [112]. The absence of imaginary frequencies for all ligands indicated
that the resulted optimized geometries correspond to true minima. The ligand–receptor
systems were built using Autodock Tools 1.5.6 [ 113], with only polar hydrogens added
to the receptor structure, which was kept rigid. In contrast, the ligands were allowed full
flexibility: 13 torsion angles were set for posaconazole, 4 for FUM, 8 for KTZ, and 14 for the
KTZ-FUM cocrystal.
To ensure accurate binding of the studied ligands to the active site of sterol 14- α
demethylase, the active site indicated by the original inhibitor in the crystallized complex
was first validated. This was achieved by removing the original inhibitor from the crystal-
lized ligand–receptor complex and performing a molecular docking scan using a search box
that encompassed the entire receptor. The redocked original ligand was overlaid onto the
crystallized complex, confirming the binding site position. Further, for the actual docking,
the search box was centered at coordinates (x,y,z) = (192, 3, 38) of size 26× 26 × 26 Å, and a
grid spacing of 1 Å, containing the validated binding site. Finally, the ligands were docked
to sterol 14-α demethylase using the Autodock Vina algorithm [85].
5. Conclusions
The focus for successful pharmaceutical drug development lies in the improvement of
the physicochemical and pharmacokinetic properties of the API without compromising its
pharmacological activity. The previously formulated cocrystal of the antifungal BCS class II
drug Ketoconazole with Fumaric acid by crystal engineering resulted in an enhancement of
the aqueous solubility (i.e., a 100-fold increase) and stability both in solid form and suspen-
sion as compared to the parent drug. Consequently, to evaluate the cocrystal antimycotic
efficiency, the present work reports the successful development of both cocrystallization
processes by cooling and mechanochemical synthesis. Furthermore, laboratory scale-up
processes were carried out at 1 g batch size by both methods, and delivered the pure
cocrystal in high yields of up to 90%.
Biological assays in vitro showed improved viability and oxidative-induced damage
of the cocrystal over KTZ on human dermal fibroblasts and hepatocarcinoma cells; in vivo,
on Wistar rats, the cocrystal increased oral KTZ bioavailability with transient minor bio-
chemical increases in transaminases and without histological liver alterations. Locally
Int. J. Mol. Sci. 2024, 25, 13346 23 of 28
applied on Balb C mice ears, the cocrystal induced no epicutaneuous sensitization and
showed a slight anti-inflammatory effect.
Molecular docking showed that KTZ, FUM, and the cocrystal interact with the sterol
14α-demethylase (CYP51) enzyme from the pathogenic yeast Candida albicans through a
combination of hydrogen bonds and hydrophobic interactions. Among all studied systems,
the KTZ-FUM cocrystal interacted more effectively with the enzyme, and the FUM coformer
enhanced its binding affinity. The cocrystal exhibited greater chemical reactivity than the
original ligand posaconazole, as indicated by HLG and increased softness. Additionally,
KTZ’s electron-accepting capacity increased in its cocrystal form, having an HLG of 3.54 eV ,
thus making it more reactive than the original ligand by 1 eV .
Overall, the cocrystal showed improved physical-chemical properties combined with
enhanced biocompatibility, oral bioavailability, local anti-inflammatory effects, and pre-
dicted anti-fungal efficiency, which represent promising results for the future use of the
KTZ-FUM cocrystal in clinical studies.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/ijms252413346/s1.
Author Contributions: Conceptualization, I.B., I.K., F.A.M.; methodology, F.A.M., I.K., I.B., R.M., and
A.-L.N.; software, M.O.M., I.L., A.M.R.G., validation, I.B., F.A.M., I.K., and A.-L.N.; investigation,
I.B., R.M., V .R., A.-L.N., P .B., R.D., M.O.M., I.L., A.M.R.G., and A.S.-B.; data curation, I.B., F.A.M.;
writing—original draft preparation, I.B, F.A.M., V .R., I.K.; writing—review and editing, I.B., I.K.,
F.A.M., and A.-L.N.; supervision, I.B., F.A.M., I.K.; project administration, F.A.M.; funding acquisition,
F.A.M. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the Romanian Ministry of Research, Innovation and Digitization—
Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFIS-
CDI), projects PN-III-P1-1.1-TE-2021-0244; PN 23 24 01 02 and PN 23 24 01 05.
Institutional Review Board Statement: The animal study protocol was approved by the Ethics
Committee of the University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca and the
Veterinary Health Directorate, Romania (protocol code 329/17 08 2022).
Informed Consent Statement: Not applicable.
Data Availability Statement: The original contributions presented in this study are included in the
article; further inquiries can be directed to the corresponding authors.
Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design
of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or
in the decision to publish the results.
References
1. Ahr, G.; Voith, B.; Kuhlmann, J. Guidances related to bioavailability and bioequivalence: European industry perspective. Eur. J.
Drug Metab. Pharmacokinet. 2000, 25, 25–27. [CrossRef] [PubMed]
2. Amidon, G.L.; Lennernäs, H.; Shah, V .P .; Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: The correlation
of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413–420. [CrossRef] [PubMed]
3. Aitipamula, S.; Bolla, G. Optimizing Drug Development: Harnessing the Sustainability of Pharmaceutical Cocrystals. Mol. Pharm.
2024, 21, 3121–3143. [CrossRef] [PubMed]
4. Holm, R.; Kuentz, M.; Ilie-Spiridon, A.-R.; Griffin, B.T. Lipid based formulations as supersaturating oral delivery systems: From
current to future industrial applications. Eur. J. Pharm. Sci. 2023, 189, 106556. [CrossRef]
5. Bolla, G.; Sarma, B.; Nangia, A.K. Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of
Improved Drugs. Chem. Rev. 2022, 122, 11514–11603. [CrossRef]
6. Jin, S.; Haskins, M.M.; Deng, C.-H.; Matos, C.R.M.O.; Zaworotko, M.J. Crystal engineering of ionic cocrystals comprising Na/K
salts of hesperetin with hesperetin molecules and solubility modulation. IUCrJ. 2023, 10, 329–340. [CrossRef]
7. Byrn, S.R.; Zografi, G.; Chen, X.S. Solid-State Properties of Pharmaceutical Materials; John Wiley & Sons, Inc.: Hoboken, NJ, USA,
2017. [CrossRef]
8. Aitipamula, S.; Banerjee, R.; Bansal, A.K.; Biradha, K.; Cheney, M.L.; Choudhury, A.R.; Desiraju, G.R.; Dikundwar, A.G.; Dubey,
R.; Duggirala, N. Polymorphs, salts, and cocrystals: What’s in a name? Cryst. Growth Des. 2012, 12, 2147–2152. [CrossRef]
Int. J. Mol. Sci. 2024, 25, 13346 24 of 28
9. Burdock, G.A.; Carabin, I.G. Generally recognized as safe (GRAS): History and description. Toxicol. Lett. 2004, 150, 3–18.
[CrossRef]
10. Kavanagh, O.N.; Croker, D.M.; Walker, G.M.; Zaworotko, M.J. Pharmaceutical cocrystals: From serendipity to design to
application. Drug Discov. Today 2019, 24, 796–804. [CrossRef]
11. Heeres, J.; Backx, L.; Mostmans, J.; Van Cutsem, J. Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of
ketoconazole, a new potent orally active broad-spectrum antifungal agent. J. Med. Chem. 1979, 22, 1003–1005. [CrossRef]
12. Faergemann, J.; Borgers, M.; Degreef, H. A new ketoconazole topical gel formulation in seborrheic dermatitis: An updated review
of the mechanism. Expert Opin. Pharmacother. 2007, 8, 1365–1371. [CrossRef] [PubMed]
13. Mc Lean, K.; Bignotti, S.; Callea, M.; Cammarata-Scalisi, F.; Steger, B.; Armstrong, D.; Lagan, M.; Sinton, J.; Semeraro, F.; Kaye,
S.B.; et al. Ocular phenotype and therapeutic interventions in keratitis-ichthyosis-deafness (KID) syndrome. Ophthalmic Genet.
2024, 45, 16–22. [CrossRef] [PubMed]
14. Lombardo, G.; Enache, D.; Gianotti, L.; Schatzberg, A.F.; Young, A.H.; Pariante, C.M.; Mondelli, V . Baseline cortisol and the efficacy
of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology 2019, 110, 104420. [CrossRef]
[PubMed]
15. Kara, D.D.; Bangera, P .D.; Mehta, C.H.; Tanvi, K.; Rathnanand, M. In Silico Screening as a Tool to Prepare Drug-Drug Cocrystals
of Ibrutinib-Ketoconazole: A Strategy to Enhance Their Solubility Profiles and Oral Bioavailability. AAPS PharmSciTech. 2023, 24,
164. [CrossRef] [PubMed]
16. Choi, F.D.; Juhasz, M.L.W.; Mesinkovska, N.A. Topical ketoconazole: A systematic review of current dermatological applications
and future developments. J. Dermatolog. Treat. 2019, 30, 760–771. [CrossRef]
17. FDA Drug Safety Communication: FDA Limits Usage of Nizoral (Ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury
and Risk of Drug Interactions and Adrenal Gland Problems. 2013. Available online: https://www.fda.gov/drugs/drug-safety-
and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially (accessed
on 1 October 2024).
18. Patel, V .; Liaw, B.; Oh, W. The role of ketoconazole in current prostate cancer care. Nat. Rev. Urol. 2018, 15, 643–651. [CrossRef]
19. Li, Y.; Li, C.; Qi, X.; Yu, L.; Lin, L. Management of small cell lung cancer complicated with paraneoplastic Cushing’s syndrome: A
systematic literature review. Front. Endocrinol. 2023, 14, 1177125. [CrossRef]
20. Ryan, C.J.; Halabi, S.; Ou, S.S.; Vogelzang, N.J.; Kantoff, P .; Small, E.J. Adrenal androgen levels as predictors of outcome in
prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a cancer and leukemia group B
study. Clin. Cancer Res. 2007, 13, 2030–2037. [CrossRef]
21. Martin, F.A.; Pop, M.M.; Borodi, G.; Filip, X.; Kacso, I. Ketoconazole salt and co-crystals with enhanced aqueous solubility. Cryst.
Growth Des. 2013, 13, 4295–4304. [CrossRef]
22. Adam, J.; Yang, M.; Bauerschmidt, C.; Kitagawa, M.; O’Flaherty, L.; Maheswaran, P .; Özkan, G.; Sahgal, N.; Baban, D.; Kato,
K.; et al. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Rep. 2013, 3, 1440–1448.
[CrossRef]
23. Morata, A.; Bañuelos, M.A.; López, C.; Song, C.; Vejarano, R.; Loira, I.; Palomero, F.; Suarez Lepe, J.A. Use of fumaric acid to
control pH and inhibit malolactic fermentation in wines. Food Addit. Contam. Part A. Chem. Anal. Control Exp. Risk Assess. 2020, 37,
228–238. [CrossRef] [PubMed]
24. Comes, J.E.; Beelman, R.B. Addition of fumaric acid and sodium benzoate as an alternative method to achieve a 5-log reduction
of Escherichia coli O157:H7 populations in apple cider. J. Food Prot. 2002, 65, 476–483. [CrossRef] [PubMed]
25. Pérez-Díaz, I.M.; McFeeters, R.F. Preservation of acidified cucumbers with a natural preservative combination of fumaric acid
and allyl isothiocyanate that target lactic acid bacteria and yeasts. J. Food Sci. 2010, 75, M204–M208. [CrossRef] [PubMed]
26. Landeck, L.; Asadullah, K.; Amasuno, A.; Pau-Charles, I.; Mrowietz, U. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF)
salts for the treatment of plaque psoriasis: A review of clinical data. Arch. Dermatol. Res. 2018, 310, 475–483. [CrossRef]
27. Gold, R.; Linker, R.A.; Stangel, M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative
mechanism of action. Clin. Immunol. 2012, 142, 44–48. [CrossRef]
28. Wollina, U. Fumaric acid esters in dermatology. Indian Dermatol. Online J. 2011, 2, 111–119. [CrossRef]
29. Akao, M.; Kuroda, K. Antifungal activity of fumaric acid in mice infected with Candida albicans. Chem. Pharm. Bull. 1991, 39,
3077–3078. [CrossRef]
30. Genito, C.J.; Eckshtain-Levi, M.; Piedra-Quintero, Z.L.; Krovi, S.A.; Kroboth, A.; Stiepel, R.T.; Guerau-de-Arellano, M.; Bachelder,
E.M.; Ainslie, K.M. Dexamethasone and Fumaric Acid Ester Conjugate Synergistically Inhibits Inflammation and NF- κB in
Macrophages. Bioconjug. Chem. 2021, 32, 1629–1640. [CrossRef]
31. Choi, J.S.; Byeon, J.C.; Park, J.S. Naftopidil-fumaric acid interaction in a solid dispersion system: Improving the dissolution rate
and oral absorption of naftopidil in rats. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 95, 264–274. [CrossRef]
32. Kumari, N.; Roy, P .; Roy, S.; Parmar, P .K.; Chakraborty, S.; Das, S.; Pandey, N.; Bose, A.; Bansal, A.K.; Ghosh, A. Investigating
the Role of the Reduced Solubility of the Pirfenidone-Fumaric Acid Cocrystal in Sustaining the Release Rate from Its Tablet
Dosage Form by Conducting Comparative Bioavailability Study in Healthy Human Volunteers. Mol. Pharm. 2022, 19, 1557–1572.
[CrossRef]
33. Zhang, D.; Bian, Q.; Li, J.; Huang, Q.; Gao, J. Enhancing effect of fumaric acid on transdermal penetration of loxoprofen sodium.
Int. J. Pharm. 2020, 588, 119722. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2024, 25, 13346 25 of 28
34. Allen, F.H. The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Crystallogr. Sect. B Struct.
Sci. 2002, B58, 380–388. [CrossRef] [PubMed]
35. Kacso, I.; Rus, L.M.; Martin, F.; Miclaus, M.; Filip, X.; Dan, M. Solid-state compatibility studies of Ketoconazole-Fumaric acid
co-crystal with tablet excipients. J. Therm. Anal. Calorim. 2021, 143, 3499–3506. [CrossRef]
36. Sarangi, S.; Remya, P .N.; Damodharan, N. Advances in solvent based cocrystallization: Bridging the gap between theory and
practice. J. Drug Delivery. Sci. Technol. 2024, 95, 105619. [CrossRef]
37. Wojciech, B.; Janusz, W. The Metastable Zone of aqueous solutions. CHEMIK 2014, 68, 198–201.
38. Schwartz, A.M.; Myerson, A.S. Solutions and Solution Properties. In Handbook of Industrial Crystallization, 2nd ed.; Myerson, A.S.,
Ed.; Butterworth-Heinemann: Woburn, MA, USA, 2002; pp. 1–31. [CrossRef]
39. Saha, A.; Ahangar, A.A.; Dar, A.A.; Thirunahari, S.; Parambil, J.V . Pharmaceutical Cocrystals: A Perspective on Development and
Scale-up of Solution Cocrystallization. Cryst. Growth Des. 2023, 23, 7558–7581. [CrossRef]
40. O’Sullivan, A.; Kelly, S.; Bhattacharya, S.; Ryan, K.M.; Collins, M.N.; Padrela, L. Polymorph selection of pharmaceutical cocrystals
via bench-top and continuous production techniques. Int. J. Pharm. 2024, 663, 124596. [CrossRef]
41. Madanayake, S.N.; Manipura, A.; Thakuria, R.; Adassooriya, N.M. Opportunities and Challenges in Mechanochemical Cocrystal-
lization toward Scaled-Up Pharmaceutical Manufacturing. Org. Process Res. Dev. 2023, 27, 409–422. [CrossRef]
42. Balak, D.M.W.; Piaserico, S.; Kasujee, I. Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: A review of the
hepatic effects of systemic therapies. Psoriasis Targets Ther.2021, 11, 151–168. [CrossRef]
43. Litjens, N.H.R.; Rademaker, M.; Ravensbergen, B.; Thio, H.B.; Dissel, J.T.; Nibbering, P .H. Effects of monomethylfumarate on
dendritic cell differentiation. Br. J. Dermatol. 2006, 154, 211–217. [CrossRef]
44. Ocaña, C.M.; Bernal, M.; Yang, C.; Caro, C.; Dom ínguez, A.; Vu, H.S.; Cárdenas, C.; García-Martín, M.L.; DeBerardinis, R.J.;
Quesada, A.R.; et al. New insights in the targets of action of dimethyl fumarate in endothelial cells: Effects on energetic
metabolism and serine synthesis in vitro and in vivo. Commun. Biol. 2023, 6, 1084. [CrossRef] [PubMed]
45. Erler, K.; Krafczyk, N.; Steinbrenner, H.; Klotz, L.O. Selective activation of cellular stress response pathways by fumaric acid
esters. FEBS Open Bio 2024, 14, 1230–1246. [CrossRef] [PubMed]
46. Adachi, M.; Hinatsu, Y.; Kusamori, K.; Katsumi, H.; Sakane, T.; Nakatani, M.; Wada, K.; Yamamoto, A. Improved dissolution and
absorption of ketoconazole in the presence of organic acids as pH-modifiers. Eur. J. Pharm. Sci. 2015, 76, 225–230. [CrossRef]
[PubMed]
47. Martin, F.; Pop, M.; Kacso, I.; Grosu, I.G.; Miclau¸ s, M.; Vodnar, D.; Lung, I.; Filip, G.A.; Olteanu, E.D.; Moldovan, R.; et al.
Ketoconazole-p-aminobenzoic Acid Cocrystal: Revival of an Old Drug by Crystal Engineering. Mol. Pharm. 2020, 17, 919–932.
[CrossRef]
48. Adachi, M.; Hinatsu, Y.; Kusamori, K.; Katsumi, H.; Sakane, T.; Nakatani, M.; Wada, K.; Yamamoto, A. Effects of Manufacturing
Methods on Dissolution and Absorption of Ketoconazole in the Presence of Organic Acid as a pH Modifier. AAPS PharmSciTech.
2017, 18, 1203–1212. [CrossRef]
49. Dudhipala, N.; Ay, A.A. Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability
through oral administration for management of fungal infections. Chem. Phys. Lipids 2020, 232, 104953. [CrossRef]
50. Endo, E.H.; Makimori, R.Y.; Companhoni, M.V .P .; Ueda-Nakamura, T.; Nakamura, C.V .; Dias Filho, B.P . Ketoconazole-loaded poly-
(lactic acid) nanoparticles: Characterization and improvement of antifungal efficacy in vitro against Candida and dermatophytes.
J. Mycol. Med. 2020, 30, 101003. [CrossRef]
51. Raut, S.; Gargate, N.; Ugale, S.; Gujar, K.N.; Kapare, H. Formulation and Development of hyaluronic acid based gel with
Ketoconazole-loaded nanostructured lipid carriers in fungal infection. Pharm. Nanotechnol. 2023, 11, 344–354. [CrossRef]
52. Stricker, B.H.; Blok, A.P .; Bronkhorst, F.B.; Van Parys, G.E.; Desmet, V .J. Ketoconazole-associated hepatic injury. A clinicopatholog-
ical study of 55 cases. J. Hepatol. 1986, 3, 399–406. [CrossRef]
53. Bok, R.A.; Small, E.J. The treatment of advanced prostate cancer with ketoconazole: Safety issues. Drug Saf. 1999, 20, 451–458.
[CrossRef]
54. Khoza, S.; Moyo, I.; Ncube, D. Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and
Griseofulvin in Rats. J. Toxicol. 2017, 2017, 6746989. [CrossRef] [PubMed]
55. Tits, J.; Berman, J.; Cammue, B.P .A.; Thevissen, K. Combining Miconazole and Domiphen Bromide Results in Excess of Reactive
Oxygen Species and Killing of Biofilm cells. Front. Cell Dev. Biol. 2021, 8, 617214. [CrossRef] [PubMed]
56. Lundqvist, J.; Hellman, B.; Oskarsson, A. Fungicide prochloraz induces oxidative stress and DNA damage in vitro. Food Chem.
Toxicol. 2016, 91, 36–41. [CrossRef] [PubMed]
57. Kobayashi, D.; Kondo, K.; Uehara, N.; Otokozawa, S.; Tsuji, N.; Yagihashi, A.; Watanabe, N. Endogenous reactive oxygen species
is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. 2002, 46, 3113–3117. [CrossRef] [PubMed]
58. Petricca, S.; Celenza, G.; Luzi, C.; Cinque, B.; Lizzi, A.R.; Franceschini, N.; Festuccia, C.; Iorio, R. Synergistic Activity of
Ketoconazole and Miconazole with Prochloraz in Inducing Oxidative Stress, GSH Depletion, Mitochondrial Dysfunction, and
Apoptosis in Mouse Sertoli TM4 Cells. Int. J. Mol. Sci. 2022, 23, 5429. [CrossRef]
59. Wewering, F.; Jouy, F.; Wissenbach, D.K.; Gebauer, S.; Blüher, M.; Gebhardt, R.; Pirow, R.; von Bergen, M.; Kalkhof, S.; Luch, A.;
et al. Characterization of chemical-induced sterile inflammation in vitro: Application of the model compound ketoconazole in a
human hepatic co-culture system. Arch. Toxicol. 2017, 91, 799–810. [CrossRef]
Int. J. Mol. Sci. 2024, 25, 13346 26 of 28
60. Petricca, S.; Carnicelli, V .; Luzi, C.; Cinque, B.; Celenza, G.; Iorio, R. Oxidative Stress, Cytotoxic and Inflammatory Effects of
Azoles Combinatorial Mixtures in Sertoli TM4 Cells. Antioxidants 2023, 12, 1142. [CrossRef]
61. do Prado, C.C.A.; Queiroz, L.G.; da Silva, F.T.; de Paiva, T.C.B. Toxicological effects caused by environmental relevant concentra-
tions of ketoconazole in Chironomus sancticaroli (Diptera, Chironomidae) larvae evaluated by oxidative stress biomarkers. Comp.
Biochem. Physiol. C Toxicol. Pharmacol. 2023, 264, 109532. [CrossRef]
62. do Prado, C.C.A.; Queiroz, L.G.; da Silva, F.T.; de Paiva, T.C.B. Ecotoxicological effect of ketoconazole on the antioxidant system
of Daphnia similis. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2021, 246, 109080. [CrossRef]
63. Olayaki, L.; Adeyemi, W.; Alabi, Q.; Okeleji, L.; Shoyoye, A.; Sampson, E.; Sulaiman, F.; Abdul-Azeez, A.-R.; Omoniyi, J. Melatonin
ameliorates some biochemical alterations following ketoconazole administration in rats. J. Basic. Clin. Physiol. Pharmacol. 2020, 31,
20190155. [CrossRef]
64. Periasamy, S.; Liu, C.T.; Chien, S.P .; Chen, Y.C.; Liu, M.Y. Daily sesame oil supplementation mitigates ketoconazole-induced
oxidative stress-mediated apoptosis and hepatic injury. J. Nutr. Biochem. 2016, 37, 67–75. [CrossRef] [PubMed]
65. Hamza, A.A.; Gamel, M.; Abdalla, A.; Abdalla, Y.; Amin, A. Gentiana lutea attenuates hepatotoxicity induced by ketoconazole in
rats by fortifying the cellular antioxidant defense system. JoBAZ 2023, 84, 1. [CrossRef]
66. Kaur, G.; Shivanandappa, T.B.; Kumar, M.; Kushwah, A.S. Fumaric acid protect the cadmium-induced hepatotoxicity in rats:
Owing to its antioxidant, anti-inflammatory action and aid in recast the liver function. Naunyn-Schmiedeberg’s Arch. Pharmacol.
2020, 393, 1911–1920. [CrossRef] [PubMed]
67. Kuroda, K.; Akao, M.; Terao, K. Fumaric acid enhances DNA synthesis of rat hepatocytes by counteracting the toxicities of
mitomycin C and aflatoxin B1. Jpn. J. Cancer Res. 1986, 77, 750–758. [PubMed]
68. Kuroda, K.; Teranishi, S.; Akao, M. Toxicity of mitomycin C and anti-intoxication by fumaric acid in liver and kidney cellular fine
structure. Gan 1982, 73, 656–660. [PubMed]
69. Levey, S.; Lasichak, A.G.; Brimi, R.; Orten, J.M.; Smyth, C.J.; Smith, A.H. A study to determine the toxicity of fumaric acid. J. Am.
Pharm. Assoc. (Sci. Ed.) 1946, 35, 298–304. [CrossRef]
70. Ketoconazole. React. Wkly. 2024, 1999, 212. [CrossRef]
71. Available online: https://reference.medscape.com/drug/nizoral-ketoconazole-342592#4 (accessed on 1 October 2024).
72. Van Cutsem, J.; Van Gerven, F.; Cauwenbergh, G.; Odds, F.; Janssen, P .A. The antiinflammatory effects of ketoconazole. A
comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-
pigs. J. Am. Acad. Dermatol. 1991, 25, 257–261. [PubMed]
73. Katsambas, A.; Antoniou, C.; Frangouli, E.; Avgerinou, G.; Michailidis, D.; Stratigos, J. A double-blind trial of treatment of
seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br. J. Dermatol. 1989, 121, 353–357.
[CrossRef]
74. Beetens, J.R.; Loots, W.; Somers, Y.; Coene, M.C.; De Clerck, F. Ketoconazole inhibits the biosynthesis of leukotrienesin vitro and
in vivo. Biochem. Pharmacol. 1986, 35, 883–891. [CrossRef]
75. Kanda, N.; Watanabe, S. Ketoconazole suppresses prostaglandin E(2)-induced cyclooxygenase-2 expression in human epidermoid
carcinoma A-431 cells. J. Investig. Dermatol. 2002, 119, 174–181. [CrossRef] [PubMed]
76. Chen, Y.; Chen, H.-N.; Wang, K.; Zhang, L.; Huang, Z.; Liu, J.; Zhang, Z.; Luo, M.; Lei, Y.; Peng, Y.; et al. Ketoconazole exacerbates
mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J. Hepatol. 2019, 70, 66–77.
[CrossRef] [PubMed]
77. Prado-Carrillo, O.; Arenas-Ramírez, A.; Llaguno-Munive, M.; Jurado, R.; Pérez-Rojas, J.; Cervera-Ceballos, E.; Garcia-Lopez, P .
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. Int. J. Mol. Sci. 2022, 23, 7715.
[CrossRef] [PubMed]
78. Danescu, S.; Filip, G.A.; Moldovan, R.; Olteanu, D.; Nagy, A.; Filip, X.; Martin, F.; Kacso, I.; Baldea, I. Ketoconazole-p aminoben-
zoic cocrystal, an improved antimycotic drug formulation, does not induce skin sensitization on the skin of BALBc mice.
Inflammopharmacology 2021, 29, 721–733. [CrossRef]
79. Kreiling, R.; Hollnagel, H.M.; Hareng, L.; Eigler, D.; Lee, M.S.; Griem, P .; Dreessen, B.; Kleber, M.; Albrecht, A.; Garcia, C.; et al.
Comparison of the skin sensitizing potential of unsaturated compounds as assessed by the murine local lymph node assay
(LLNA) and the guinea pig maximization test (GPMT). Food Chem. Toxicol. 2008, 46, 1896–1904. [CrossRef]
80. Frohwein, T.A.; Sonnenburg, A.; Zuberbier, T.; Stahlmann, R.; Schreiner, M. Unsaturated compounds induce up-regulation of
CD86 on dendritic cells in the in vitro sensitization assay LCSA. Arch. Toxicol. 2016, 90, 927–936. [CrossRef]
81. Shelanski, M.V .; Phillips, S.B.; Potts, C.E. Evaluation of cutaneous reactivity to recently marketed dermatologic products.Int. J.
Dermatol. 1996, 35, 137–140. [CrossRef]
82. Liu, J.; Warshaw, E.M. Allergic contact dermatitis from ketoconazole. Cutis 2014, 94, 112–114. [PubMed]
83. Martínez-Doménech, A.; García-Legaz-Martínez, M.; Valenzuela-Oñate, C.; Magdaleno-Tapial, J.; Zaragoza-Ninet, V .; Sánchez-
Carazo, J.L.; Pérez-Ferriols, A. Photoallergic contact dermatitis to topical ketoconazole. J. Eur. Acad. Dermatol. Venereol. 2020, 34,
e499–e501. [CrossRef]
84. Hiendrawan, S.; Wahyu Hartanti, A.; Veriansyah, B.; Widjojokusumo, E.; Tjandrawinata, R.R. Solubility enhancement of
ketoconazole via salt and cocrystal formation. Int. J. Pharm. Sci. 2015, 7, 160–164.
85. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with new scoring function, efficient
optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2024, 25, 13346 27 of 28
86. Stăncioiu, L.; Gherman, A.M.R.; Brezes, tean, I.; Dina, N.E. Vibrational spectral analysis of sorafenib and its molecular docking
study compared to other TKIs. J. Mol. Struct. 2022, 1248, 131507. [CrossRef]
87. Gherman, A.M.R.; Dina, N.E.; Chi s, , V . Cheminformatiocs study on Structural and bactericidal activity of latest generation
β-lactams on widespread pathogens. Int. J. Mol. Sci. 2022, 23, 12685. [CrossRef] [PubMed]
88. Mehta, J.; Borkhataria, C.; Patel, A.; Manek, R.; Patel, N.; Sakhiya, D.; Shanishchara, K.; Mistry, B. Para-hydroxy benzoic acid
conformer enable enhanced solubility, dissolution, and antifungal activity of ketoconazole cocrystals. J. Pharm. Innov. 2023, 18,
1602–1615. [CrossRef]
89. Koopmans, T. Über die uordnung von wellenfunktionen und eigenwerten zu den einzelnen elektronen eines atoms. Physica 1934,
1, 104–113. [CrossRef]
90. Parr, R.G.; Pearson, R.G. Absolute hardness: Companion parameter to absolute electronegativity. J. Am. Chem. Soc. 1983, 105,
7512–7516. [CrossRef]
91. Parr, R.G.; Donnelly, R.A.; Levy, M.; Palke, W.E. Electronegativity: The density functional viewpoint. J. Chem. Phys. 1978, 68,
3801–3807. [CrossRef]
92. Maynard, A.T.; Huang, M.; Rice, W.G.; Covell, D.G. Reactivity of the HIV-1 nucleocapsid protein p7 zinc finger domains from the
perspective of Density Functional Theory. Proc. Natl. Acad. Sci. USA 1998, 95, 11578–11583. [CrossRef]
93. Parr, R.G.; Szentp ály, L.V .; Liu, S. Electrophilicity Index.J. Am. Chem. Soc. 1999, 121, 1922–1924. [CrossRef]
94. Baldea, I.; Olteanu, D.E.; Bolfa, P .; Ion, R.M.; Decea, N.; Cenariu, M.; Baniu, M.; Sesarman, A.V .; Filip, A.G. Efficiency of
photodynamic therapy on WM35 melanoma with new synthetic porphyrins: Role of chemical structure, intracellular targeting
and antioxidant defense. J. Photochem. Photobiol. B Biol. 2015, 151, 142–152. [CrossRef]
95. European Medicines Agency. Assessment Report. 2014. Available online: https://www.ema.europa.eu/en/documents/
assessment-report/ketoconazole-hra-epar-public-assessment-report_en.pdf (accessed on 1 October 2024).
96. Huang, C.; Colaizzi, J.; Bierman, R.; Woestenborghs, R.; Heykants, J. Pharmacokinetics and dose proportionality of ketoconazole
in normal volunteers. Antimicrob. Agents Chemother. 1986, 30, 206–210. [CrossRef] [PubMed]
97. Nair, A.B.; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 2016, 7, 27–31.
[CrossRef] [PubMed]
98. Lubach, J.W.; Chen, J.Z.; Hau, J.; Imperio, J.; Coraggio, M.; Liu, L.; Wong, H. Investigation of the rat model for preclinical 960
evaluation of pH dependent oral absorption in Humans. Mol. Pharm. 2013, 10, 3997–4004. [CrossRef] [PubMed]
99. Wang, K.; Wu, Y.; Chi, Z.; Shu, C.; Li, L.; Wei, J.; Tao, L.; Ma, P .; Ding, L. A highly sensitive LC-MS/MS method for determination
of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical
administration. J. Pharm. Biomed. Anal. 2016, 128, 504–509. [CrossRef]
100. David, L.; Moldovan, B.; Vulcu, A.; Olenic, L.; Perde-Schrepler, M.; Fischer-Fodor, E.; Florea, A.; Crisan, M.; Chiorean, I.; Clichici,
S.; et al. Green synthesis, characterization and anti-inflammatory activity of silver nanoparticles using European black elderberry
fruits extract. Colloids Surf. B Biointerfaces 2014, 122, 767–777. [CrossRef]
101. Noble, J.E.; Bailey, M.J. Quantitation of protein. Methods Enzymol. 2009, 463, 73–95. [CrossRef]
102. Tordesillas, L.; Goswami, R.; Benedé, S.; Grishina, G.; Dunkin, D.; Järvinen, K.M.; Maleki, S.J.; Sampson, H.A.; Berin, M.C. Skin
exposure promotes a Th2-dependent sensitization to peanut allergens. J. Clin. Investig. 2014, 124, 4965–4975. [CrossRef]
103. Dunn, B.J.; Rusch, G.M.; Siglin, J.C.; Blaszcak, D.L. Variability of a mouse ear swelling test (MEST) in predicting weak and
moderate contact sensitization. Fundam. Appl. Toxicol. 1990, 15, 242–248. [CrossRef]
104. Husain, M.; Boermans, H.J.; Karrow, N.A. Mesenteric lymph node transcriptome profiles in BALB/c mice sensitized to three
common food allergens. BMC Genom. 2011, 6, 12. [CrossRef]
105. Thorne, P .S.; Hawk, C.; Kaliszewski, S.D.; Guiney, P .D. The Noninvasive Mouse Ear Swelling Assay I. Refinements for Detecting
Weak Contact Sensitizers. Fundam. Appl. Tox. 1991, 17, 807–820. [CrossRef]
106. AAT Bioquest, Inc. 2024, Quest Graph™ IC50 Calculator. AAT Bioquest. Available online: https://www.aatbio.com/tools/ic50-
calculator (accessed on 1 October 2024).
107. Hargrove, T.Y.; Wawrzak, Z.; Friggeri, L.; Lepesheva, G.I. Crystal Structure of Sterol 14-Alpha Demethylase (CYP51) from
a Pathogenic Yeast Candida albicans in Complex with the Antifungal Drug Posaconazole. 2017. Available online: https:
//www.wwpdb.org/pdb?id=pdb_00005fsa (accessed on 1 October 2024).
108. Becke, A.D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993, 98, 5648–5652. [CrossRef]
109. Lee, C.; Yang, W.; Parr, R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density.
Phys. Rev. B. 1988, 37, 785–789. [CrossRef] [PubMed]
110. Vosko, S.H.; Wilk, L.; Nusair, M. Accurate spin-dependent electron liquid correlation energies for local spin density calculations:
A critical analysis. Can. J. Phys. 1980, 58, 1200–1211. [CrossRef]
111. Stephens, P .J.; Devlin, F.J.; Chabalowski, C.F.; Frisch, M.J. Ab initio calculation of vibrational absorption and circular dichroism
spectra using Density Functional force fields. J. Phys. Chem. 1994, 98, 11623–11627. [CrossRef]
Int. J. Mol. Sci. 2024, 25, 13346 28 of 28
112. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V .; Petersson, G.A.;
Nakatsuji, H.; et al. Gaussian 16 Rev. C.01/C.02; Gaussian, Inc.: Wallingford, CT, USA, 2019.
113. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and Autodock Tools4:
Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.